

INNOVATION FOR HEALTH HEALTH

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

Stock

Our Vision

Our vision is to be the leading provider of
the most innovative and effective
solutions for our customers.

Our Mission

Our mission is to deliver the highest quality
products and services to our customers.

Contents

2	C	a	.	ma	
4		a	a		
		a	a	m	D
				a	A a
3		s	a		D
41	.	m	C	C	a s a m
42	.	m	C	C	a s a m C m
43	.	m	C	C	a s a m a a
4	.	m	C	C	a s a m C a
4	.	m	C	C	a s a m Ca
4				m C	C a a a s a m
				D	

2 2 (徐曉亮)

(龔平)¹

W D (潘東)

（梁劍峰）

$$Ca \text{ (干燥)}^3$$

W a (沐海)

~~~~~

3. (江寧)

W. J. G. (1993) *Journal of the Royal Society of Medicine*, 86, 1033-1034.

## Stock Abbreviation

AS A

## Share Listing

AS : S a a S a

S C : 600196

S a : S a m

S C : 02196

## A Share Registrar and Transfer Office in the PRC

C a S D & C a C a m (C S DCC)

S a a B a

C a a B

166 a a a

✓ D

S a a, C a

## H Share Registrar and Transfer Office in Hong Kong

S m

54, C

183 a a

## Company's Website

// a ma. m

<sup>1</sup> A 30 2020

<sup>2</sup> 17 a a 2020

<sup>3</sup> 21 a a 2020

<sup>4</sup> A 21 a a 2020

<sup>5</sup> 30 2020

<sup>6</sup> A 30 a 2020

## Financial

|                                   | Six months ended 30 June |        |
|-----------------------------------|--------------------------|--------|
|                                   | 2020                     | 2019   |
|                                   | RMB million              | B m    |
| <b>Operating results</b>          |                          |        |
| Revenue                           | 13,965                   | 14,085 |
| Cost of sales                     | 7,749                    | 8,486  |
| Gross profit                      | 1,292                    | 1,490  |
| Selling and distribution expenses | 2,302                    | 2,196  |
| Administrative expenses           | 1,715                    | 1,516  |
| B. DA                             | 3,566                    | 3,483  |
| <b>Profitability</b>              |                          |        |
| Gross profit margin               | 55.49%                   | 60.25% |
| Operating profit margin           | 9.25%                    | 10.58% |
| Net profit margin                 | 13.67%                   | 12.92% |
| <b>Earnings per share</b>         |                          |        |
| Basic                             | 0.95                     | 0.95   |
| Diluted                           | 0.95                     | 0.95   |

## FINANCIAL REVIEW

During the year, the Company's financial performance was generally in line with the market. The Company's revenue increased by 0.85% to B13,965 million, while net profit decreased by 13.56% to B0.67 million. The Company's operating profit decreased by 13.10% to B1,715 million, while the profit attributable to shareholders decreased by 4.83% to B2,302 million. The Company's cash and cash equivalents decreased by 2.6% to B4,071 million. The Company's total assets decreased by 29.15% to B9,952 million, while the total liabilities decreased by 29.15% to B9,894 million. The Company's equity decreased by 29.15% to B9,894 million. The Company's financial position remained stable, and the Company's financial performance was generally in line with the market.

During the year, the Company's financial performance was generally in line with the market. The Company's revenue increased by 0.85% to B13,965 million, while net profit decreased by 13.56% to B0.67 million. The Company's operating profit decreased by 13.10% to B1,715 million, while the profit attributable to shareholders decreased by 4.83% to B2,302 million. The Company's cash and cash equivalents decreased by 2.6% to B4,071 million. The Company's total assets decreased by 29.15% to B9,952 million, while the total liabilities decreased by 29.15% to B9,894 million. The Company's equity decreased by 29.15% to B9,894 million. The Company's financial position remained stable, and the Company's financial performance was generally in line with the market.

## REVENUE

During the year, the Company's revenue increased by 0.85% to B13,965 million, while net profit decreased by 13.56% to B0.67 million. The Company's operating profit decreased by 13.10% to B1,715 million, while the profit attributable to shareholders decreased by 4.83% to B2,302 million. The Company's cash and cash equivalents decreased by 2.6% to B4,071 million. The Company's total assets decreased by 29.15% to B9,952 million, while the total liabilities decreased by 29.15% to B9,894 million. The Company's equity decreased by 29.15% to B9,894 million. The Company's financial position remained stable, and the Company's financial performance was generally in line with the market.

During the year, the Company's revenue increased by 0.85% to B13,965 million, while net profit decreased by 13.56% to B0.67 million. The Company's operating profit decreased by 13.10% to B1,715 million, while the profit attributable to shareholders decreased by 4.83% to B2,302 million. The Company's cash and cash equivalents decreased by 2.6% to B4,071 million. The Company's total assets decreased by 29.15% to B9,952 million, while the total liabilities decreased by 29.15% to B9,894 million. The Company's equity decreased by 29.15% to B9,894 million. The Company's financial position remained stable, and the Company's financial performance was generally in line with the market.

D a A a

## SELLING AND DISTRIBUTION EXPENSES

D

2019. D

21.35%

B3,931 m

B4,998 m

## R&D EXPENSES AND R&D EXPENDITURE

D

2019.

41.81%

2019.

15.4%

46.27%

2019.

10.6%

25.02%

27.92%

B355 m

B1,689 m

B1,204 m

B1,541 m

B336 m

B1,059 m

B335 m

## SHARE OF PROFITS OF ASSOCIATES

D  2019. 8.03% B699 m B760 m

## PROFIT FOR THE PERIOD

| Item | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 | 1984 | 1983 | 1982 | 1981 | 1980 | 1979 | 1978 | 1977 | 1976 | 1975 | 1974 | 1973 | 1972 | 1971 | 1970 | 1969 | 1968 | 1967 | 1966 | 1965 | 1964 | 1963 | 1962 | 1961 | 1960 | 1959 | 1958 | 1957 | 1956 | 1955 | 1954 | 1953 | 1952 | 1951 | 1950 | 1949 | 1948 | 1947 | 1946 | 1945 | 1944 | 1943 | 1942 | 1941 | 1940 | 1939 | 1938 | 1937 | 1936 | 1935 | 1934 | 1933 | 1932 | 1931 | 1930 | 1929 | 1928 | 1927 | 1926 | 1925 | 1924 | 1923 | 1922 | 1921 | 1920 | 1919 | 1918 | 1917 | 1916 | 1915 | 1914 | 1913 | 1912 | 1911 | 1910 | 1909 | 1908 | 1907 | 1906 | 1905 | 1904 | 1903 | 1902 | 1901 | 1900 | 1899 | 1898 | 1897 | 1896 | 1895 | 1894 | 1893 | 1892 | 1891 | 1890 | 1889 | 1888 | 1887 | 1886 | 1885 | 1884 | 1883 | 1882 | 1881 | 1880 | 1879 | 1878 | 1877 | 1876 | 1875 | 1874 | 1873 | 1872 | 1871 | 1870 | 1869 | 1868 | 1867 | 1866 | 1865 | 1864 | 1863 | 1862 | 1861 | 1860 | 1859 | 1858 | 1857 | 1856 | 1855 | 1854 | 1853 | 1852 | 1851 | 1850 | 1849 | 1848 | 1847 | 1846 | 1845 | 1844 | 1843 | 1842 | 1841 | 1840 | 1839 | 1838 | 1837 | 1836 | 1835 | 1834 | 1833 | 1832 | 1831 | 1830 | 1829 | 1828 | 1827 | 1826 | 1825 | 1824 | 1823 | 1822 | 1821 | 1820 | 1819 | 1818 | 1817 | 1816 | 1815 | 1814 | 1813 | 1812 | 1811 | 1810 | 1809 | 1808 | 1807 | 1806 | 1805 | 1804 | 1803 | 1802 | 1801 | 1800 | 1799 | 1798 | 1797 | 1796 | 1795 | 1794 | 1793 | 1792 | 1791 | 1790 | 1789 | 1788 | 1787 | 1786 | 1785 | 1784 | 1783 | 1782 | 1781 | 1780 | 1779 | 1778 | 1777 | 1776 | 1775 | 1774 | 1773 | 1772 | 1771 | 1770 | 1769 | 1768 | 1767 | 1766 | 1765 | 1764 | 1763 | 1762 | 1761 | 1760 | 1759 | 1758 | 1757 | 1756 | 1755 | 1754 | 1753 | 1752 | 1751 | 1750 | 1749 | 1748 | 1747 | 1746 | 1745 | 1744 | 1743 | 1742 | 1741 | 1740 | 1739 | 1738 | 1737 | 1736 | 1735 | 1734 | 1733 | 1732 | 1731 | 1730 | 1729 | 1728 | 1727 | 1726 | 1725 | 1724 | 1723 | 1722 | 1721 | 1720 | 1719 | 1718 | 1717 | 1716 | 1715 | 1714 | 1713 | 1712 | 1711 | 1710 | 1709 | 1708 | 1707 | 1706 | 1705 | 1704 | 1703 | 1702 | 1701 | 1700 | 1699 | 1698 | 1697 | 1696 | 1695 | 1694 | 1693 | 1692 | 1691 | 1690 | 1689 | 1688 | 1687 | 1686 | 1685 | 1684 | 1683 | 1682 | 1681 | 1680 | 1679 | 1678 | 1677 | 1676 | 1675 | 1674 | 1673 | 1672 | 1671 | 1670 | 1669 | 1668 | 1667 | 1666 | 1665 | 1664 | 1663 | 1662 | 1661 | 1660 | 1659 | 1658 | 1657 | 1656 | 1655 | 1654 | 1653 | 1652 | 1651 | 1650 | 1649 | 1648 | 1647 | 1646 | 1645 | 1644 | 1643 | 1642 | 1641 | 1640 | 1639 | 1638 | 1637 | 1636 | 1635 | 1634 | 1633 | 1632 | 1631 | 1630 | 1629 | 1628 | 1627 | 1626 | 1625 | 1624 | 1623 | 1622 | 1621 | 1620 | 1619 | 1618 | 1617 | 1616 | 1615 | 1614 | 1613 | 1612</ |
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|--------|
|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|--------|

## PROFIT FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE PARENT

D  
m  
13.10%  
2019, m  
2019- C  
(Ba)  
(2,000)  
B100 m  
(3)  
B1,715 m  
B1,516  
B224 m



## DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

### Total Debts

A a 30 2020, a a ▼▼ B23,358 m m ▼▼ B21,137 m a a 31 D m 2019 ma

D a A a

---

Apr 30 2020

### Collateral and Blended Assets

A a 30 2020 a a

| Government          | Percentage |
|---------------------|------------|
| Current government  | 85%        |
| Previous government | 15%        |



D a A a

[illegible]

D

a B4,071 m a m m C a a am B9,894 m a

29.15%

D  $\frac{1}{2}$  ,  $\frac{1}{2}$  m a m a a :  $\frac{1}{2}$   $\frac{1}{2}$  : m C : B

| Business segment       | Revenue<br>Jan – Jun<br>2020 | 2019   | (%)   |
|------------------------|------------------------------|--------|-------|
| Research & Development | 9,952                        | 10,814 | 7.97  |
| Manufacturing          | 2,639                        | 1,793  | 47.18 |
| Sales & Marketing      | 1,359                        | 1,459  | 6.85  |

D

am B2,302 m B1,715 m 4.83% 13.10%, a

m a 2019. 5 a a ma , am : (1) m a a -

a m a 2019- C , a am a a a ; (2) m

a a a ( / ), a a a a m a (Ba ) a a am a ( C ) a

a , a a ma a a a a ; ma ( a a ) a a a a

a a a a a a (2,000 ), am B224 m a a ,

a a a B100 m ; a (3) m ma a ma , a a ma, a

a , ma a a

B

a a s am a.

a ma ; (2)

a a : (1) ma a ma a ; a (4)

m a a - - a 2.6

a ma m m a ; (3)

D  
a a 0.77% a m a a 2019. a 2020 am ▼▼ B1,461 m

D  
m  
B1,204 m  
B355 m  
41.81% a  
m a  
2019.

D

2



## Pharmaceutical manufacturing and R&D

1:

2:

3:

4:

# Management

D a A a

5: a m a a a m a m a a ( ), a (A D),  
(C a ) a a a m a (C ).

6: a a a m a a a m a m a a a a , a a a a m a  
(Ba ), m a a a (Ba a ), a m a a ( a ), m m a a ( a A ),  
a a m ( A D ), am a a (\$ Daa A ) a a am a .

7: a m a a a m m a a (Ba ) a C amam ( a ).

: a A a m a m am a , am , a am a a am

D a a a a m , a a  
a a , a a m a m a &D m a  
a a a a &D . A a ,  
a 2,300 a m m &D am, a ma 7.2% a m m  
a 248 a , m a a  
( 17 m a m a a , 2 m a m , 21 a m a  
a , 21 m a , 117 a a a a , 46 a a  
a 2 a a C m ). 22 a , 9 m a a 13  
m . A a , 6 a a a , 33 a  
a a 34 a a m a . D , a a 49 a a a  
a m a a a a &D m , 31 a a , 5 a  
a a a 7 C a a , 23 a a .

a 2020, a &D m a m a a , m a a  
a m a a a m a a CA - , a m a a  
a a a a a a &D m a a a  
a m a , a a a a &D C a 2020, a  
m a m C a , a . A a , 10 m a m a a  
( 1 m ) a 11 a a a a a a C a a , 5 m a m a  
a a 5 a a a a a a a a : 1001 a a  
a a a a DA a a D m am. a a a a A-189  
a a a 10 m a a a 8 m a a a a m a 20 a a  
a a ( C876, a a - m a CD19 CA - ) , a , m  
a a a m a a a a a a B- m m a C

a a a a a a a a a . D , A a m a  
a a a (\$ ), a m a a m a a a  
a a , a a ; a a a 12 a a m a a m a  
DA a . A a , a a m a 3 ( a a ,  
D a a a a a ) a a m a a a m D (D);  
a a a a a a m a 3 ( a a a a , Ca a a  
a a ) a a m a a a a (C A). A a a ,  
a a 23 a a a a a m a a a  
a a ( a , a : 40m , 80m ) a a a a m a (Ba )  
a a a a , a a m m a a  
a a . Am a a m a a a a , a  
a 11 a a a a a a a a a a  
C m a , m A a a a a C .D-19 m A a a a B 162 1  
B a a C a a a a a a C a a 2020. a m a ( a  
a am : a , a am C a a : 汉曲优) a a a a  
C a a a a a a a a a a a a a

A a , ma &D ma m a m a :

| No. | Name of R&D project on drugs (products) | R&D stages as at the end of the Reporting Period in the PRC |                         | R&D stages as at the end of the Reporting Period in other countries |                         |
|-----|-----------------------------------------|-------------------------------------------------------------|-------------------------|---------------------------------------------------------------------|-------------------------|
|     |                                         | R&D stage                                                   | Stage of clinical trial | R&D stage                                                           | Stage of clinical trial |
| 1   | SA-189 (Ca )                            | a C a a                                                     | a ..                    | a a a a a                                                           | a .. (L.S.)             |
| 2   | GA-411                                  | C a a                                                       | a ..                    |                                                                     |                         |
| 3   | LA-1501                                 | C a a                                                       | a ..                    | C a a                                                               | a .. (L.S.)             |
| 4   | GA-437                                  | C a a                                                       | a ..                    | C a a                                                               | a .. (L.S.)             |
| 5   | a a a                                   | C a a                                                       | a ..                    |                                                                     |                         |
| 6   | GA-159                                  | C a a                                                       | a ..                    |                                                                     |                         |
| 7   | LA-1001 (1)                             | C a a                                                       | a ..                    | C a a                                                               | a .. (L.S.)             |
| 8   | D a m                                   | C a a                                                       | a ..                    |                                                                     |                         |
| 9   | GA-647 Ca                               | A                                                           | a a                     |                                                                     |                         |
| 10  | GA-207 a                                | A                                                           | a a                     |                                                                     |                         |
| 11  | GA-011 Ca                               | A                                                           | a a                     |                                                                     |                         |
| 12  | GA-338 a (2)                            | A                                                           | a a                     | A (L.S.)                                                            | a a                     |

1: S a a a D m am L.S. DA;

2: A a a , a a a a C a a .

A a , ' &D m a a :

| No. | Type  | Name of R&D project on drugs (products) | R&D stages in China as at the end of the Reporting Period |                         | R&D stages in other countries as at the end of the Reporting Period |                         |
|-----|-------|-----------------------------------------|-----------------------------------------------------------|-------------------------|---------------------------------------------------------------------|-------------------------|
|     |       |                                         | R&D stage                                                 | Stage of clinical trial | R&D stage                                                           | Stage of clinical trial |
| 1   | B m a | ma .                                    | A                                                         |                         |                                                                     |                         |
| 2   | B m a | a ma . (2)                              | L.S. (1)                                                  | a ..                    | L.S. a a                                                            | a ..                    |
| 3   | B m a | A a m ma S .                            | L.S. a                                                    | a ..                    |                                                                     |                         |
| 4   | B m a | m a A - ma                              | C a a                                                     | a .. (3)                |                                                                     |                         |
| 5   | B m a | m a A - ma /                            | A                                                         |                         |                                                                     |                         |

Management

D a A a

| No. | Type | Name of R&D project on drugs (products)         | R&D stages in China as at the end of the Reporting Period |                         | R&D stages in other countries as at the end of the Reporting Period |                         |
|-----|------|-------------------------------------------------|-----------------------------------------------------------|-------------------------|---------------------------------------------------------------------|-------------------------|
|     |      |                                                 | R&D stage                                                 | Stage of clinical trial | R&D stage                                                           | Stage of clinical trial |
| 6   | B    | m a A - 2 D ma ...<br>ma a A                    | A                                                         |                         |                                                                     |                         |
| 7   | B    | m a A - 2 D ma ...<br>ma a A                    | C                                                         |                         |                                                                     |                         |
| 8   | B    | m a ma A -C A-4<br>a A                          | A                                                         |                         |                                                                     |                         |
| 9   | B    | m a ma A - A<br>a A                             | A                                                         |                         |                                                                     |                         |
| 10  | B    | m a ma C m<br>A -CD20 a A                       | C                                                         |                         |                                                                     |                         |
| 11  | B    | m a A - ma<br>a A                               | A                                                         |                         |                                                                     |                         |
| 12  | B    | m a A - 2 ma<br>a A ( 5)                        | C                                                         |                         | A                                                                   |                         |
| 13  | B    | m a A - ma<br>a A ( 6)                          | C                                                         |                         | A                                                                   |                         |
| 14  | B    | m a ma A -D-1<br>a A ( 7)                       | C                                                         |                         | A                                                                   |                         |
| 15  | B    | m a ma A -D- 1<br>a A                           | A                                                         |                         | C                                                                   |                         |
| 16  | B    | 22 a A                                          | C                                                         |                         |                                                                     |                         |
| 17  | B    | 55 a A                                          | C                                                         |                         |                                                                     |                         |
| 18  | B    | 56 a A                                          | A                                                         |                         |                                                                     |                         |
| 19  | C    | C m m a ma<br>A -D-1 a A<br>a m a A -<br>ma a A | C                                                         |                         |                                                                     |                         |



| No. | Type         | Name of R&D project on drugs (products)                                                                  | R&D stages in China as at the end of the Reporting Period |                         | R&D stages in other countries as at the end of the Reporting Period |                         |
|-----|--------------|----------------------------------------------------------------------------------------------------------|-----------------------------------------------------------|-------------------------|---------------------------------------------------------------------|-------------------------|
|     |              |                                                                                                          | R&D stage                                                 | Stage of clinical trial | R&D stage                                                           | Stage of clinical trial |
| 20  | C m a<br>a m | C m a m a ma<br>A →D-1 a A<br>. a m a A -<br>ma a A<br>.                                                 | A                                                         |                         | a a                                                                 |                         |
| 21  | C m a<br>a m | C m a m a ma<br>A →D-1 a A<br>. a C m a<br>(C a +5 a a -<br>a m a A a<br>a a a a a C<br>Ca ma            | C                                                         | a a                     | ↗ a ...                                                             |                         |
| 22  | C m a<br>a m | C m a m a ma<br>A →D-1 a A<br>. C m a<br>(Ca a - ) a a a m<br>a a - a a ma C<br>Ca                       | C                                                         | a a                     | ↗ a ...                                                             | C a a ↗ a ...           |
| 23  | C m a<br>a m | C m a m a ma<br>A →D-1 a A<br>. C m a a a a -/<br>A a a m a Ca                                           | C                                                         | a a                     | ↗ a ...                                                             |                         |
| 24  | C m a<br>a m | C m a m a ma<br>A →D-1 a A<br>. C m a<br>(Ca a -A m - a a )<br>a a - a m a<br>A a a a a a<br>a - ma C Ca | C                                                         | a a                     | ↗ a ...                                                             | C a a ↗ a ...           |
| 25  | C m a<br>a m | C m a m a ma<br>A →D-1 a A<br>. A m - a a<br>a a a m A a C a<br>Ca A a -<br>C m a                        | C                                                         | a a                     | ↗ a ..                                                              |                         |

1: A 2020, m a a a 2,000 a a , 2,000 m  
a a 500m /50m/ ma ( a a ) a A. 2020,  
m a a a a ma ( a a ) a A.

[illegible]

Management

D a A a

3: a ... a m a a a a a m .

4: S ma a a a a a a ... a a C a a .

5: A a a a a a a a a a C a; m , a a a a

Aa S. DA a a a .

6: A a a a a a a a C a a ; m , a a a a a a S.

DA a a a a a a a a a m .

7: A a a a a a m a a a a C a; a a a a a a

m a a m a a a - m ma a m a a a a a a a C

a a ; a a a a a B a a a a a C a.

: A a a a a a A a a.

: S a a a a a C a.

10: a a m m a ma a -D-1 m a a a m a a - ma

m a a a m a a a a a a C a a a a a a a m

m a a am - ma a , a a a a m a a a a ma a a

a a am m .

A a , ma &D a :

| No. | Type  | Name of R&D project on drugs (products) | Indications                                                                                               | R&D stages as at the end of the Reporting Period in the PRC | Stage of clinical trial as at the end of the Reporting Period in the PRC |
|-----|-------|-----------------------------------------|-----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|--------------------------------------------------------------------------|
| 1   | C m a | A-824                                   | a m a a<br>( D - B)<br>m a<br>( D - B) a a<br>a m /<br>a a m<br>a a m<br>a a a<br>a a<br>C mm<br>m a ( 1) | C a a a                                                     | a a                                                                      |
| 2   | C m a | A a m a a a                             | m a a a<br>m m a<br>m a a a<br>a a<br>a a<br>a a<br>a a<br>a a                                            | C a a a<br>A a a                                            | a a                                                                      |
| 3   | C m a | a a a                                   | a a m<br>a a<br>a ma - a<br>a a a a<br>a a a a                                                            | a a a<br>a a a                                              | a a                                                                      |
| 4   | C m a | B m a                                   | .m a ma a<br>a a a                                                                                        | a a a                                                       | a a                                                                      |
| 5   | C m a | a a                                     | a m                                                                                                       | C a a a                                                     | a a                                                                      |
| 6   | C m a | a a                                     | a a                                                                                                       | a a a                                                       | a a                                                                      |

| No.    | Type               | Name of R&D project<br>on drugs (products) | Indications                   | R&D stages as at<br>the end of the<br>Reporting Period<br>in the PRC | Stage of clinical<br>trial as at the end<br>of the Reporting<br>Period in the PRC |
|--------|--------------------|--------------------------------------------|-------------------------------|----------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| 7      | C m a              | a a                                        | ma a a                        | AD                                                                   |                                                                                   |
| 8      | a                  | 002                                        | a a a a                       | A a                                                                  |                                                                                   |
|        | a                  |                                            | a                             | a a                                                                  |                                                                                   |
|        |                    |                                            | S a a a                       | A a                                                                  |                                                                                   |
|        |                    |                                            |                               | a a                                                                  |                                                                                   |
| 9      | ma                 | a C .D-19 m\A a<br>(B 162 1)( 2)           | ma C .D-19                    |                                                                      |                                                                                   |
| 1:     | A a a              | , a a                                      | a a a a m a ma a a            | am                                                                   | a a a                                                                             |
|        | A;                 |                                            |                               |                                                                      |                                                                                   |
| 2:     | A a a              | , C .D-19 m\A a                            | (B 162 1) a a a a m A         | a a C                                                                | a a , a                                                                           |
|        | a mm               | a . a a.                                   |                               |                                                                      |                                                                                   |
|        |                    | a a a m a a a m a m                        |                               |                                                                      | a a                                                                               |
|        |                    | a a a m m . a a m a m a                    |                               |                                                                      | a a                                                                               |
| m      | a a a m a m a a a  |                                            | a m m a a a m a m a           |                                                                      | a a m a                                                                           |
| a ma   | a m a m a a a      |                                            | a m &D,                       |                                                                      | a , a m                                                                           |
| a ma   | a a ,              |                                            | a a m a a ma a ,              |                                                                      | a a                                                                               |
| m a    | a a .              |                                            | a m m a a m a m               |                                                                      | a                                                                                 |
|        | a m a m a a a      |                                            | , a ma a m , a ma a m , - - a |                                                                      |                                                                                   |
| ( S)   | a , m m a          |                                            | a (CA-A) a a . D              |                                                                      |                                                                                   |
|        | a a a m m          |                                            | a ( ), a a a a                |                                                                      |                                                                                   |
| m      | a , m m S S ma m m |                                            | a , m a a m , a               |                                                                      |                                                                                   |
| a a    | D A m a a a        |                                            | m a ma a m m , m              |                                                                      |                                                                                   |
| a a    | a m a a            |                                            | a , a , a am m                |                                                                      | a a                                                                               |
| a a    | m                  |                                            | a m.                          |                                                                      |                                                                                   |
| A a    |                    |                                            | a a a ma a ma a               |                                                                      | a                                                                                 |
|        | C a                |                                            | a a a a a a a a a a a a       |                                                                      | L.S., L.a                                                                         |
|        | a ,                |                                            | a a a a m a a ma a ma a       |                                                                      | m . A a                                                                           |
|        | , m                |                                            | a 10                          |                                                                      | a a a                                                                             |
| a      | L.S., L.a          |                                            | a a ; 4 a ma a ma a           |                                                                      | a a a                                                                             |
| a a /  | a a                |                                            | L.S., L.a , A a a , B a a     |                                                                      | . 1                                                                               |
|        | a a m a a          |                                            | 3                             |                                                                      |                                                                                   |
| - ; 1  | a a m a            |                                            | a a a a a Ca a a a            |                                                                      | L.S. DA; 1 -                                                                      |
| a      | a a a m            |                                            | L.S. DA; a                    |                                                                      | a m a                                                                             |
| a a ma | a                  |                                            | S a a B a ma a                |                                                                      | (D-) 02                                                                           |
| m      | L.a                |                                            | , S a a a                     |                                                                      |                                                                                   |

# Management

D a A a

D  
a m ma m a a , a a a m a m a ma m, a  
ma am ma a a , a a a m ma . A  
a m a ma am a 5,800 , a a ma a  
a m a ma am a 1,000 m m ma , ma a a  
- m a, ma m a, a a a ma a m , a -  
ma a m a a am , a a a a ma a m m a a ; a  
a m a a a ma a ma , a a ma ; a a , ma  
a a m ma a m , a a a ma ; a ,  
a a a a S am, a , a a a a S am'  
ma , a ma a a a am a am m a a -  
a a - a -a a a A a, a m a m  
a m A a ma ; a am m , ma a m L.S. a , m -  
ma a m a a a ma a ma , a a ' ama a a a a  
ma .

D  
a a 47.18% a m a B2,639 m m m a a m a a m ,  
a 74.69% a m a 2019; m am B510 m ,  
a 88.22% a m a 2019. - - a a B434 m ,  
ma a a m a - a m , a a 2019- C , a  
am a a a , a a a m a a a a ma . a a  
m a a m Da a a m S a- , a , a  
a a a 2020, 30 Da a m a , a a ma 18,500 a  
a m C a a a , a - - a .

D  
a a m a a m A a a a m a ( - a a a ).  
a 2019- C a a a a a a a a a , L.S.,  
L.S. A a a , m 2019- C a a am m  
a B500 m a , m C D-19 a m , a  
ma a a a a m , a a a  
am a , a a a a a a , a  
a C a , - m a m a a a .

D  
a m am m a m S am a a a a C D-19  
m a am L.S. \$6 m ( a a a a m S am a am L.S. \$72  
a - - a . m a a a a a , S am a  
ma ( a m ma ), , a a , a &D m ma  
a am m a a am a a . a  
a 2020, am D ma C a , am a a ma Am a ) a a  
m ma .

a 2020, a ma m m m a a a  
a ma a a a a a a a a 44 a a  
a a a a a m a , a a m a  
, m - , a ma . ( a a ) a  
a a .

[illegible]

D                      a    A    a

a a ma , a m s a m 30 , m a a a m a a  
 , a m a a ma a 7,047, a a  
 a 2020, s a m' a m a a ma ma a a a , a ▼▼ B11,016 m ,  
 a a 24.59% a m a a a .

C.D-19

a m a , S a m a m a m a  
a ma m a a a a - a . D  
a m a a ma m a m a  
a , a a , a a m a a a , a  
a m a ma a m .. a 2020, \$ a m' m a  
a a ▼▼ B35,873 m , a - - a 23.59%.

[illegible]

a m a , a m m 4. a , a m m  
m m a a ma a a , a a aa a ma a m, a  
m m m a a a m m a m a a ma . B ma  
a ma , aaa a a a a ,  
a a m , a . D , a ama a  
&D a a ma a m a ma a a ma a m a m . A  
a a - a m a a a a ma a m,  
a m, a m a a a a - a , a a  
a m

[illegible]



# Management

D a A a

a a a  
(1) n

n

: m C : B

| Items       | Amount for<br>the period | Amount<br>for the<br>corresponding<br>period of<br>last year | Period-on-<br>period<br>change<br>(%) | Reasons |
|-------------|--------------------------|--------------------------------------------------------------|---------------------------------------|---------|
|             | 13,965                   | 14,085                                                       | 0.85                                  |         |
| C a         | 6,216                    | 5,599                                                        | 11.02                                 |         |
| S a         | 3,931                    | 4,998                                                        | 21.35                                 | 1       |
| A m a       | 1,322                    | 1,148                                                        | 15.16                                 |         |
| a a m       | 1,204                    | 849                                                          | 41.81                                 | 2       |
| a           | 428                      | 547                                                          | 21.76                                 | 3       |
| \ a a m a a | 1,461                    | 1,450                                                        | 0.77                                  |         |
| \ a a m m a | -2,379                   | 1,079                                                        | 120.55                                | 4       |
| \ a a m a a | 827                      | 496                                                          | 266.75                                | 5       |

1: D a ma a a a a a m , a a am ma a  
ma m , a ( ma ( a a )) a  
(A a m a a a (S ) a a ma ( a A ), ). ma a - -  
a a : a a ;  
m a , a a ; a a

2: a a &D a ma a , ma m a a a m  
a , a a m a a a m

3: - - a a ma - - a a a a a  
- a a a a a m a am m a  
m a a a

4: a a - - a am a m a a a m  
a

5: a a m a a a a a - m mm a a  
a a





Management

D a A a

... a ... s4 m ... a ... a ...  
(1)

... : m C : B

| Principal operations by segments           |         |               |                         |                                        |                                              |                                         |
|--------------------------------------------|---------|---------------|-------------------------|----------------------------------------|----------------------------------------------|-----------------------------------------|
| By segments                                | Revenue | Cost of sales | Gross profit margin (%) | Period-on-period change in revenue (%) | Period-on-period change in cost of sales (%) | Period-on-period change in gross margin |
| ... a ... a ... a ... a ... &D<br>( ... 1) | 9,952   | 3,754         | 62.28                   | 7.97                                   | 3.79                                         | a 4.27<br>a                             |
| ... a ... a ... m ... a ... a              | 2,639   | 1,309         | 50.40                   | 47.18                                  | 49.21                                        | a 0.68<br>a                             |
| ... a ... a ... ( ... 2)                   | 1,359   | 1,130         | 16.82                   | 6.85                                   | 4.68                                         | a 9.16<br>a                             |

| Principal operations by products                             |         |               |                         |                                        |                                              |                                         |
|--------------------------------------------------------------|---------|---------------|-------------------------|----------------------------------------|----------------------------------------------|-----------------------------------------|
| Products                                                     | Revenue | Cost of sales | Gross profit margin (%) | Period-on-period change in revenue (%) | Period-on-period change in cost of sales (%) | Period-on-period change in gross margin |
| ... a ... m ... a ... m ... a ... a ...<br>( ... 3)          | 1,767   | 278           | 84.26                   | 2.19                                   | 4.51                                         | a 0.38<br>a                             |
| ... a ... a ... m ... a ... a ... a ... ( ... 4)             | 422     | 119           | 71.89                   | 59.94                                  | 71.10                                        | a 1.83<br>a                             |
| ... a ... a ... a ... a ... a ... ( ... 5)                   | 1,800   | 631           | 64.93                   | 22.77                                  | 1.68                                         | a 7.52<br>a                             |
| ... a ... a ... a ... a ... m ... a ... a ... ( ... 6)       | 755     | 48            | 93.63                   | 38.35                                  | 16.94                                        | a 1.64<br>a                             |
| ... a ... a ... a ... a ... a ... m ... a ... a ... ( ... 7) | 1,248   | 484           | 61.20                   | 9.49                                   | 20.22                                        | a 3.46<br>a                             |
| ... a ... a ... a ... a ... m ... a ... a ... a ... ( ... )  | 247     | 20            | 91.74                   | 41.03                                  | 0.42                                         | a 3.37<br>a                             |
| ... a ... m ... a ... a ... a ... m ... a ...                | 452     | 330           | 27.11                   | 32.97                                  | 31.29                                        | a 1.79<br>a                             |

|                           |                   | Principal operations by geographical locations |               |                         |                                        | Period-on-period            |                                         |
|---------------------------|-------------------|------------------------------------------------|---------------|-------------------------|----------------------------------------|-----------------------------|-----------------------------------------|
| By geographical locations |                   | Revenue                                        | Cost of sales | Gross profit margin (%) | Period-on-period change in revenue (%) | change in cost of sales (%) | Period-on-period change in gross margin |
| C                         | ▼▼ <sup>a</sup> a | 9,894                                          | 4,093         | 58.63                   | 8.30                                   | 11.40                       | a 7.32                                  |
|                           | a                 | 4,071                                          | 2,123         | 47.84                   | 23.53                                  | 10.29                       | a 6.26                                  |
|                           | 1: .63            |                                                |               |                         |                                        |                             | a                                       |

D a A a

$$(1) \quad a_1, a_2, \dots, a_n, a_{n+1}, \dots, a_m$$

W

$$L \begin{array}{|c|} \hline \square \\ \hline \end{array} : m \quad C \quad : \quad \begin{array}{|c|} \hline \square \\ \hline \end{array} B$$

| Name of subsidiary | Nature of business | Major products or services                                                                                                                                                                                                                                                          | Registered capital | Total assets | Net assets | Revenue | Operating profit | Net profit |
|--------------------|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------|------------|---------|------------------|------------|
| 上海福安泰医药有限公司        | 医药研发               | 阿莫西林, 头孢曲松钠, 注射用头孢曲松钠, 注射用头孢唑肟钠, 注射用头孢噻肟钠, 注射用头孢哌酮钠, 注射用头孢哌酮舒巴坦钠, 注射用头孢唑林钠, 注射用头孢噻吩钠, 注射用头孢拉定, 注射用头孢呋辛钠, 注射用头孢他啶, 注射用头孢吡肟, 注射用头孢美唑, 注射用头孢替唑, 注射用头孢替安, 注射用头孢唑肟钠, 注射用头孢噻肟钠, 注射用头孢哌酮钠, 注射用头孢哌酮舒巴坦钠, 注射用头孢唑林钠, 注射用头孢噻吩钠, 注射用头孢拉定, 注射用头孢呋辛钠, 注射用头孢他啶, 注射用头孢吡肟, 注射用头孢美唑, 注射用头孢替唑, 注射用头孢替安 | 197                | 5,753        | 3,514      | 2,414   | 485              | 416        |
| 上海福安泰医药有限公司        | 医药研发               | 阿莫西林, 头孢曲松钠, 注射用头孢曲松钠, 注射用头孢唑肟钠, 注射用头孢噻肟钠, 注射用头孢哌酮钠, 注射用头孢哌酮舒巴坦钠, 注射用头孢唑林钠, 注射用头孢噻吩钠, 注射用头孢拉定, 注射用头孢呋辛钠, 注射用头孢他啶, 注射用头孢吡肟, 注射用头孢美唑, 注射用头孢替唑, 注射用头孢替安                                                                                                                                | 440                | 5,176        | 2,770      | 2,825   | 441              | 369        |
| 上海福安泰医药有限公司        | 医药研发               | 阿莫西林, 头孢曲松钠, 注射用头孢曲松钠, 注射用头孢唑肟钠, 注射用头孢噻肟钠, 注射用头孢哌酮钠, 注射用头孢哌酮舒巴坦钠, 注射用头孢唑林钠, 注射用头孢噻吩钠, 注射用头孢拉定, 注射用头孢呋辛钠, 注射用头孢他啶, 注射用头孢吡肟, 注射用头孢美唑, 注射用头孢替唑, 注射用头孢替安                                                                                                                                | N/A                | 6,956        | 5,645      | 1,476   | 562              | 419        |
| 上海福安泰医药有限公司        | 医药研发               | 阿莫西林, 头孢曲松钠, 注射用头孢曲松钠, 注射用头孢唑肟钠, 注射用头孢噻肟钠, 注射用头孢哌酮钠, 注射用头孢哌酮舒巴坦钠, 注射用头孢唑林钠, 注射用头孢噻吩钠, 注射用头孢拉定, 注射用头孢呋辛钠, 注射用头孢他啶, 注射用头孢吡肟, 注射用头孢美唑, 注射用头孢替唑, 注射用头孢替安                                                                                                                                | 510                | 2,626        | 1,864      | 599     | 64               | 61         |

:        a        aa        a        a        a        aa        a        am        a        a        a        a        aa        .

S a a S a B S m

$$L \begin{array}{|c|} \hline \square \\ \hline \end{array} : m \quad C \quad : \quad \begin{array}{|c|} \hline \square \\ \hline \end{array} B$$

| Name of subsidiary | Nature of business | Major products or services | Registered capital | Total assets | Net assets | Revenue | Net profit |
|--------------------|--------------------|----------------------------|--------------------|--------------|------------|---------|------------|
| S. A. (1)          | ma &D              |                            | 543                | 5,536        | 3,708      | 110     | 448        |
| C. A. (2)          |                    |                            | 50                 | 2,528        | 1,728      | 686     | 41         |
| S. A. (1)          | ma &D              |                            | N/A                | 2,745        | 2,302      | 504     | 40         |

7:        a    a    s    a    a        a    s    am    a        a        m        2020    m

2:        a a   C a                a                a                a                a a   a am   a                a                a                a                a a

(2) n 10% n ' n

L : m C : B

| Name of investee | Nature of business | Principal activities | Registered capital | Total assets | Net assets | Revenue | Operating profit |
|------------------|--------------------|----------------------|--------------------|--------------|------------|---------|------------------|
| S a m. a         | a m a              | a m a                | 100                | 307,273      | 84,008     | 203,765 | 4,808            |

(3) n n ( , n , n )

|                 |            |           |       |         |             |       |       |
|-----------------|------------|-----------|-------|---------|-------------|-------|-------|
| A               | 27 a 2020, | a , a     | a ,   | a       | a a m       | a ,   |       |
|                 | a          | a         | 50%   | a       | a           | a     | . A a |
|                 |            | a         | 100%  | a       | a           | a     |       |
| 8 A 2020,       | a m a      | a , a     | a ,   | a s a a | A m         | C . C |       |
| (B ), a         | a m a      | a . a a   | 51%   | a       | C . C a m a | a     |       |
| C . C (B ). A a |            | a , a m a | a . a | 100%    |             |       |       |
| C . C a m a a . |            |           |       |         |             |       |       |
| a               | a          | a         | a     |         |             |       | a     |
| :               |            |           |       |         |             |       |       |

L : m C : B

| Name of subsidiary | Acquired through    | Net assets (as at the end of Reporting Period) | Net profit (from date of acquisition/merger up to the end of Reporting Period) | Date of acquisition/merger |
|--------------------|---------------------|------------------------------------------------|--------------------------------------------------------------------------------|----------------------------|
| a a a              | a                   | 47                                             | 25                                                                             | 19 a 2020                  |
| C . C a m a a      | a                   | 4                                              | 6                                                                              | 9 a 2020                   |
| :                  | a a a a a a a a m a | a a a a a a a                                  |                                                                                |                            |

D                      a    A    a

D a s a

29 a 2020, a Ca a , a m a , a m .

$\alpha$                        $\alpha$                        $\beta$                        $\alpha$                        $\beta$                        $\alpha$

 : m
  : B

|     | Name of subsidiary       | Disposed through | Net assets as at date of disposal | Net profit from beginning of Reporting Period to date of disposal | Date of disposal |
|-----|--------------------------|------------------|-----------------------------------|-------------------------------------------------------------------|------------------|
|     | C a a                    | D a              | 0                                 | 29                                                                | a 2020           |
| m   |                          |                  |                                   |                                                                   |                  |
|     | a ma a ma a a &D, a      |                  |                                   | m a a m a a ,                                                     |                  |
|     | a a , a ma a a a .       |                  | a a a ma a ma a a &D, m a         |                                                                   |                  |
|     | a m a a .                |                  | a a a m                           | m a a                                                             |                  |
|     | a a am a a .             |                  |                                   |                                                                   |                  |
|     | m                        |                  | m -a a &D,                        | a ma a a ,                                                        |                  |
|     | a a m a a a ,            |                  | a a ma a m , - a , a a            |                                                                   |                  |
|     | a a ma a a a a a a a a , |                  |                                   | a a                                                               |                  |
|     | m ,m a a a a a a a a ;   |                  |                                   | a a a                                                             |                  |
|     | a a aa a m a a a a .     |                  |                                   |                                                                   |                  |
|     | a a a a m a ma a ,       |                  |                                   |                                                                   | a                |
|     | a a a a ma ,             |                  |                                   |                                                                   |                  |
| m   |                          |                  |                                   |                                                                   |                  |
| A a |                          |                  | 30,925 m                          | m ' m a                                                           |                  |
|     | a m a a ,                |                  | a aa a ma                         |                                                                   |                  |

## 2. Business Outlook for the Second Half of 2020

a 2020, a C D-19 a m a ma a a  
 a a m a a m a a a  
 a m a a m a a

. a 2020, a a , m a &D, a  
 a ma a a a a , a ma ma a ,  
 a a ma m, a m m a a , a m  
 a a m / a m a m a m , a  
 m a . A am m, m , a, a a , a  
 a a ma ' m s a a a a , a 2020, C m a  
 a m m m s m a B a a s C mm , a a  
 C m a ' a a a a ma ma .

ma a a & a a a

2020, a a a m , a a a  
a &D a a a a a a a a a  
m a a a a a a a m a a  
a a , a a

a m a ma , m , a a ,  
a ma am , a m a a , am , a ma ( a / ), A a m ma  
a a . ( C876, ... a - ma CD19 CA - ) a , ma a  
' ma a a a a ; a a a a a a  
A a m a a a (S ), a a a , a a a C .D-19 a  
; a a a ma' , m m a a  
. a , D a a a a , a a a a  
a a ma ; a a 11 a a a a  
a m ( a a , a a a a m a , a  
ma a a , am a , m ma a , am a a , a am aa  
a , a am a , am a , a m a , a a ) a  
ma a a a , a a ma a m a ma a a m  
a a ma m .

2020, a a , a a - a a  
a m , a ma a a , a a a  
a m m - , m - - - a , - - a , a a a a (C  
a , a a a ). a a a a a a a  
a a m a . m , a a  
&D ma , m m m a a a a a

- a a , a a &D a m a m .  
a a a m m m C a a , ma a m a  
m m ma m a ma a ma a .

1. a) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 84

a 2020, a m &D, ma a a m a , a , a am  
 m , a a a a a m a a , a a  
 a m a

S am a a a a a a a m a m a , a a a  
 m a a , a m a a a a a m m a . S am a a  
 a a a a a m m a m a m a m a m  
 a a a a a a a a a a a a m a m  
 , m a m a a a a a a a a m  
 a a a m a a a a a a a a a a a a a  
 a a a a a a a a a a a a a a a a a

**V**a  
a m,  
m  
a  
a m a  
m a  
a m a ,  
a  
m a a , a  
a . a  
m a a , a

# Management

D a A a

a a a m a ma a a a m  
a m m a a a a am, a ma a  
a a a , a a a a a  
a a m a

a a s<sup>9</sup>  
a 2020, m s a ' a m m a  
a a a, a ma a a a m- a ma a m a a a a  
a a a a m a a m m a ma a a a m a m a -  
a (D ) a - a a a ( B S). m a a m a a a ,  
a a a , a a , a ma a a a , a m a ma  
m , a a a , a a a m a a a  
m a m a a a a a a a a a a m  
a a a s a a a a a a C  
C m s a\* (重慶星榮整形醫院), m ' a C a\* (徐州婦兒醫院), s a a s a -  
C ' a\* (上海星晨兒童醫院) a , a m a a  
a a

a m  
a l a a a a a a  
a 2020, a a a a m s a m a ma a a  
m a , a a m a a a s a m a ma a a m a

a a  
a 2020, a a a m a a a a , m  
a a a , a a a m , a a a a

## 3. Potential Risks

a a a a a m m  
a ma a m a a a C, a m  
a m , m a mm a a a a a a , a , a  
a m a , a a a ma a , a a a  
m a ma a , m a a a m a , a ma a ma m  
a a a a a ma , a a a ma m a  
a m m a a m a a m a a a a ,  
a m a , a a , ma m , m a a a ,  
a a , a m m a a a m , a m  
a a a C a a a a a ma a , a  
a a a m  
m m a , &D a a - m a a , a a m  
a a a a m - a ma a ma a  
a ma m a m a m a m  
a a a a a m ma a , a m  
m a m a a m



a a , a ma m a , a ma a m a  
 , a m a a - . A a a a  
 a , m a a m a a , a a  
 m , m ma a m , a am a  
 a .

### ii. a

m m a m, S a a , ma - a a a  
 ma a m m a a m a ma a m a a ma  
 . C m a m a ma m  
 , a a m a a am , a a m  
 a a , a m m a a m a , a  
 a m a ma a ma a m a ma  
 a a m a a a ma a m a m  
 m a a a a a a a a a  
 m, ma a a ma a ma a a  
 a ma , ma a a a , m ma  
 a ma a a , C a' a' C a m a a  
 m a ma a ma a ) a m a a a m a a  
 a a a a , m a m a a ma a m am a  
 a a ma a m a a a , a a am m, a a a m m  
 a a a ma a m a a a a , ma a a a ,  
 a ma , a

a , a ma m a S a , m a ,  
 a a a a , a a m m a a a m  
 a a a a a a a a a a m ma  
 a A a, m a m a ma a m ,  
 m , a a a m  
 a , a a m a , a m a  
 a a - , a a a a m m , m  
 , a a a &D a a a m , a  
 m m a , a a a a a ma , a a  
 a ma m a a a , a a ma a .

### iii. a a a

(1) &  
 D m a m a a , a a a a a a a  
 &D a ma a , a &D a a a m , ma ,  
 , a . D &D a a a a , &D a  
 ma ma ma , a a a  
 m a a , a m a a a m ma  
 a , a a a a m  
 a , m m a m a a , &D a a  
 a a m m a m m &D , a  
 m a am . a , a m  
 a a a a a a ,  
 a a &D ma a ma a ma .

## Management

D a A a

(2)

/

ma a , m a a a a mm , a a a a a  
a a a a m a m a m  
a a ma m a ma a m a m a a a /  
a a m , a m m a a ma  
a a ma a , a a ,  
a , a ma a a a a a  
m a a a a a a m a m m a a a  
ma a m a m , a a , a a a ma a , m a , a  
a a a a a m a a a a  
a a a a , a , ma a a a m  
a a a a a a a a a ma a m  
a a a a  
a a m ma m a ma a am , m a a  
a a a a m a , m a m a a a  
am a a a m a ma a , a m a a ma  
, ma a a , a a ma a a a  
m .  
a , a a ma a m , a  
m a a m m a a a m a m a a ma a m a ma a a  
a m &D a , a a a a a ma , a a  
m a m , a m a  
a .

(3)

ma a a a m a  
, m a a a , a a m a a  
, m a a a ma a m a a , a , a , a a

... a. a l<sup>m</sup> ...

(1)

ma a a m m m a a a a , am a  
a ma , ma a a m m , a m m a  
a a a . A am m , a m a a  
ma a m a a a , a m a a  
ma a m , m a a a a a , ma , a a ,  
a a a m a a ,  
a ma a m .

(2)

a a a a a a a a a , m a ,  
a a a a a a a a a a a a  
a a , m a a a ma a m m a a a  
a a m a , a ma a a a .

... a. ...

a a a , ma a a a a a a ,  
a , a a m a a a m a a a a . C a  
a a a a a a a a m a a a a a  
m , a a a a m a a a m .  
m a a a ma a a , a a a a B a  
a a a a a a a a m a a  
a a a a .

... l<sup>m</sup> ...

5 a a a a a a ma a m a , a ma a  
a a a a .

#### 4. Other Events

201 54 a ... 54 a ...  
A a m a C m a , 195 m 2019,  
(a / a a ) a a C m a ( a a / a C m a ) a ma 12 m mm m 195 m 2019  
( ), a a a a , m a a am a a a a B100 m . a  
a a a a a a a a a a 2019 a a a a  
a a a a 2% a a C m a a a 195 m 2019 ( . . 2,562,898,545 a ) (a  
a a m a C m a a 12-m a 2% a m  
a C m a ). A a , m m a 2019 a a a  
a a a a 16,369,500 a C m a a a a  
am a ma B369.81 m , a ma 0.64% a C m a a a 19  
5 m 2019.

D                      a    A    a

**Figure 6**

**a**

2020,  $\Delta$  = -0.6%.

**b**

2020,  $\Delta$  = -0.3%.

A...a a C m a ' - m mm a a a m - m  
 A a a ( s 2020 \S 325) a A a a  
 ( s 2020 \S 677) a a 2020, am a C m a '  
 - m mm a a m - m B5 . s am a 2 a  
 mm m a a a , a C m a ma a  
 a .

A 2020, C5 C A a C a B a S a a  
 a ma a ( ) C , \* ( a 2020\A.701), a a a a  
 C m a ' a a B5 a am a  
 a 24 m m a C5 C' a a , a C m a ma a a  
 a

30 D m 2019, S a a , am , a  
 a a ma, a C m a a a S a B.

D , C m a a S - a a S a  
 S a a a ma a ( ) C ., .\*( a 2020\ . 417) m . a a C a D a .6( S

## RESULTS AND DIVIDENDS

As at 30 September 2020, the Company's total assets were RMB41,777 million, total liabilities were RMB1,580,500 million, and total equity was RMB40,197 million. The Company's total assets, total liabilities, and total equity were RMB41,777 million, RMB1,580,500 million, and RMB40,197 million, respectively, as at 30 September 2020.

## PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

### Sell back of "17 Fosun 01" Corporate Bond

On 5 November 2020, the Company completed the sell back of RMB1,580,500,000 of "17 Fosun 01" Corporate Bond. The Company received the principal amount of RMB1,580,500,000 and the interest of RMB10,919,500. The Company's total assets, total liabilities, and total equity were RMB41,777 million, RMB1,580,500 million, and RMB40,197 million, respectively, as at 30 September 2020. The Company's total assets, total liabilities, and total equity were RMB41,777 million, RMB1,580,500 million, and RMB40,197 million, respectively, as at 30 September 2020.

## DIRECTORS

The Company's Board of Directors consists of the following members:

### Executive Directors

Mr. Chen Qizhi (陳啟宇) (Chairman)  
 Ms. Yao Fang (姚方) (Vice Chairman)  
 Ms. Wu Yifang (吳以芳) (Executive Director)

### Non-executive Directors

Mr. Xu Xiaoliang (徐曉亮)  
 Mr. Gao Ping (龔平)  
 Mr. Pan Donghui (潘東輝)

### Independent Non-executive Directors

Mr. Jiang Hui (江惠)  
 Mr. Huang Tianyu (黃天祐)  
 Ms. Li Ling (李玲)  
 Mr. Tang Yuliang (湯谷良)

On 17 November 2020, the Company completed the sell back of RMB1,580,500,000 of "17 Fosun 01" Corporate Bond. The Company received the principal amount of RMB1,580,500,000 and the interest of RMB10,919,500. The Company's total assets, total liabilities, and total equity were RMB41,777 million, RMB1,580,500 million, and RMB40,197 million, respectively, as at 30 September 2020. The Company's total assets, total liabilities, and total equity were RMB41,777 million, RMB1,580,500 million, and RMB40,197 million, respectively, as at 30 September 2020.

## Statutory D

## SUPERVISORS

A a  $\frac{1}{2}$  S C mm S a a :

▼▼ . a (任情) ( n )  
 ▼▼ . Ca (曹根興)  
 ▼▼ . a m (管一民)

## CHANGE OF INFORMATION OF DIRECTORS AND SUPERVISORS

▼▼. C, a D, a a a - Ba ( : 01761), a m a  
S a, 30 2020.

▼▼ a a , a - D , a a a - a ▼▼ C m a m \* (招金礦業股份有限公司) ( : 01818), a m a S a , 24 A ▼ 2020.

公司) ( : 00755), a m a \$ a , 23 A 2020. m \* (上海證大房地產有限

申通地鐵股份有限公司) ( : 600834), a m a S a a S a , 9 . a 2020. C . , . \* (上海

D. 本公司之子公司長飛光纖光纜股份有限公司（統一信用代碼：601869, 06869），於2020年12月31日，本公司對該公司之長期應收款項為人民幣13,000,000.00元。

▼ 限公司) ( : 600623), a m a S a a S a , 24 2020. \* (上海華誼集團股份有

$\Sigma a_i^2 = 13.51(2)$

## SHARE INCENTIVE SCHEMES

## Gland Pharma Share Option Incentive Scheme

S a a , am ma , a a ma S a . S m 25 2019. a  
 a ma S a S m () a m a a a ma , () a  
 m a a a a ma, ( ) m , a ( ) a m  
 a .

S  
a  
170,444 a /ama a , 1.1% a m  
a /ama a a /ama S a S m .S m a  
a /ama S a S m , a /ama a m a /ama a a

D                       $\frac{1}{2}$  ,        a        a        a                      a  $\frac{1}{2}$  a m a                      s     m     a

•

(5) D                  ,                  a                  a                  a ma\$ a                  \$ m





## INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES

As at 30 June 2020, the following persons are known to have interests or short positions in the shares or underlying shares of the Company, which are required to be disclosed under Chapter 10 of the Securities and Futures Ordinance (SFO) and Part 2 of the Securities and Futures Commission (SFC) Listing Rules:

| Name of Shareholders | Nature of interest | Class of Shares | Number of Shares <sup>(1)</sup> | Approximate percentage of Shares in relevant class of Shares |
|----------------------|--------------------|-----------------|---------------------------------|--------------------------------------------------------------|
| B                    | Beneficial         | Ordinary Shares | 48,803,000 ( ) <sup>(2)</sup>   | 8.84%                                                        |
| B                    | Beneficial         | Ordinary Shares | 938,095,290 ( ) <sup>(2)</sup>  | 46.65%                                                       |
| B                    | Beneficial         | Ordinary Shares | 48,803,000 ( ) <sup>(2)</sup>   | 8.84%                                                        |
| B                    | Beneficial         | Ordinary Shares | 938,095,290 ( ) <sup>(2)</sup>  | 46.65%                                                       |
| B                    | Beneficial         | Ordinary Shares | 48,803,000 ( ) <sup>(2)</sup>   | 8.84%                                                        |
| B                    | Beneficial         | Ordinary Shares | 938,095,290 ( ) <sup>(2)</sup>  | 46.65%                                                       |
| B                    | Beneficial         | Ordinary Shares | 48,803,000 ( ) <sup>(2)</sup>   | 8.84%                                                        |
| B                    | Beneficial         | Ordinary Shares | 938,095,290 ( ) <sup>(2)</sup>  | 46.65%                                                       |
| B                    | Beneficial         | Ordinary Shares | 48,803,000 ( ) <sup>(2)</sup>   | 8.84%                                                        |
| B                    | Beneficial         | Ordinary Shares | 938,095,290 ( ) <sup>(2)</sup>  | 46.65%                                                       |
| B                    | Beneficial         | Ordinary Shares | 114,075 ( )                     | 0.01%                                                        |
| B                    | Beneficial         | Ordinary Shares | 38,723,000 ( )                  | 7.02%                                                        |
| B                    | Beneficial         | Ordinary Shares | 38,707,016 ( )                  | 7.01%                                                        |
| B                    | Beneficial         | Ordinary Shares | 28,195,990 ( )                  | 5.11%                                                        |
|                      |                    |                 | 782,000 ( )                     | 0.14%                                                        |

(1) ( )

(1) ( ) ; ( ) ( )

(2) The percentage of shares held by the substantial shareholders is calculated based on the total number of shares of the Company in issue as at 30 June 2020, which is 550,000,000 shares. The percentage of shares held by the substantial shareholders is 71.09%.

## DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

During the period from 1 January 2020 to 30 June 2020, none of the directors or supervisors of the Company has exercised any rights to acquire shares or debentures of the Company.

# Statutory D

## MODEL CODE FOR SECURITIES TRANSACTIONS

C m a a a      C a a m a      C a      a a a .  
a ma      D , a D      m a a m      a a a        
C a      C      .

## COMPLIANCE WITH THE CG CODE

A a m a      a      S a a S      a a      S      a ,      C m a a ma  
m a      A      A a ,      a a a a      a ,      S      a a S  
a a      .      C m a mm      a m      a a      a , a  
m      a ma a m a      a      a      m      a      C m a .  
a      a a a a      C m a a a      a      C C .      C m a a  
m      a a a      a      C C      .

## REVIEW OF INTERIM RESULTS AND INTERIM REPORT BY THE AUDIT COMMITTEE

21 a a 2020 . a Ca      a a -      D a a m m      a mm      am a . A  
m      B a ,      a m      a , a -      D , a a a      a m m      a  
mm      B a a a .

30 2020 . a      a a -      D a a m m      a mm      a m  
a a m . A      m      B a ,      a m      .      , a -      D , a a  
a a m m      a mm      B a a a .

A a      , a mm      C m a m      . a a ( a ma ), a -  
D      . a a , a -      D .  
ma      a mm      a a m      a a      , ma a m a a  
m      C m a , a      mm a a a      B a .

a mm      C m a a      a      m a      m  
30 2020.

B a      B a  
Chen Qiyu  
n

S a a ,      C  
25 A      2020

# Interim Condensed Consolidated

S a m



For the six months ended 30 June 2020

|                                                                                 |    | For the six months ended 30 June |             |
|---------------------------------------------------------------------------------|----|----------------------------------|-------------|
|                                                                                 |    | 2020                             | 2019        |
|                                                                                 |    | RMB'000                          | B'000       |
|                                                                                 |    | (Unaudited)                      | (Unaudited) |
| <b>REVENUE</b>                                                                  | 5  | 13,965,179                       | 14,085,146  |
| C a                                                                             |    | (6,215,872)                      | (5,598,983) |
|                                                                                 |    | 7,749,307                        | 8,486,163   |
| m                                                                               | 6  | 180,429                          | 109,724     |
| S a                                                                             |    | (3,931,067)                      | (4,998,448) |
| A m a                                                                           |    | (1,322,239)                      | (1,147,889) |
| a a m                                                                           |    | (1,204,425)                      | (849,383)   |
| .m a m a a a                                                                    |    | (42,765)                         | (21,918)    |
| a                                                                               | 7  | 603,622                          | 389,686     |
|                                                                                 |    | (52,138)                         | (45,617)    |
| m                                                                               |    | 96,436                           | 86,650      |
| a                                                                               | 8  | (427,878)                        | (546,940)   |
| S a a :                                                                         |    | (46,558)                         | (25,933)    |
| A a                                                                             |    | 698,964                          | 760,055     |
| <b>PROFIT BEFORE TAX</b>                                                        | 9  | 2,301,688                        | 2,196,150   |
| . m a                                                                           | 10 | (392,081)                        | (376,521)   |
| <b>PROFIT FOR THE PERIOD</b>                                                    |    | 1,909,607                        | 1,819,629   |
| A a :                                                                           |    | 1,714,710                        | 1,516,120   |
| - a                                                                             |    | 194,897                          | 303,509     |
|                                                                                 |    | 1,909,607                        | 1,819,629   |
| <b>EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT</b> | 12 |                                  |             |
| Ba                                                                              |    | RMB0.67 Yuan                     | B0.59 /a    |
| D                                                                               |    | RMB0.67 Yuan                     | B0.59 /a    |

## m 30 2020

42 S4 a.  $(a^{-1})^m = a^{-m}$   $a^m a^{-m} = a^{m-m} = a^0 = 1$

# Interim Condensed Consolidated

Statement of Financial Position

as at 30 June 2020

30 June 2020

|                                                                        |    | 30 June<br>2020<br>RMB'000<br>(Unaudited) | 31 Dec<br>2019<br>RMB'000<br>(Audited) |
|------------------------------------------------------------------------|----|-------------------------------------------|----------------------------------------|
| <b>NON-CURRENT ASSETS</b>                                              |    |                                           |                                        |
| Property, plant and equipment                                          | 13 | 11,313,846                                | 10,720,960                             |
| Intangible assets                                                      |    | 2,389,837                                 | 2,454,742                              |
| Investments in subsidiaries                                            |    | 9,093,050                                 | 9,013,990                              |
| Investments in associates                                              |    | 9,238,300                                 | 9,036,246                              |
| Financial assets at fair value through profit or loss                  |    | 356,204                                   | 381,332                                |
| Financial assets at fair value through other comprehensive income      |    | 21,712,444                                | 20,491,557                             |
| Financial assets at amortised cost                                     |    | 60,945                                    | 107,709                                |
| Deferred tax assets                                                    |    | 1,851,891                                 | 1,983,155                              |
| Other non-current assets                                               |    | 236,457                                   | 196,095                                |
|                                                                        |    | 1,300,703                                 | 1,273,605                              |
|                                                                        |    | 57,553,677                                | 55,659,391                             |
| <b>CURRENT ASSETS</b>                                                  |    |                                           |                                        |
| Financial assets at fair value through profit or loss                  | 14 | 4,561,539                                 | 3,940,537                              |
| Financial assets at fair value through other comprehensive income      |    | 5,271,488                                 | 4,607,722                              |
| Financial assets at amortised cost                                     |    | 1,628,029                                 | 1,420,087                              |
| Financial assets at cost                                               |    | 992,812                                   | 456,651                                |
| Financial assets at fair value through profit or loss                  |    | 354,915                                   | 445,103                                |
| Other current assets                                                   |    | 9,750,416                                 | 9,533,268                              |
|                                                                        |    | 22,559,199                                | 20,403,368                             |
| <b>CURRENT LIABILITIES</b>                                             |    |                                           |                                        |
| Financial liabilities at fair value through profit or loss             | 15 | 2,864,017                                 | 2,397,315                              |
| Financial liabilities at fair value through other comprehensive income |    | 6,116,649                                 | 5,376,193                              |
| Financial liabilities at amortised cost                                | 16 | 12,404,601                                | 8,560,202                              |
| Financial liabilities at cost                                          |    | 138,571                                   | 143,786                                |
| Other current liabilities                                              |    | 527,652                                   | 503,683                                |
|                                                                        |    | 487,052                                   | 452,587                                |
|                                                                        |    | 22,538,542                                | 17,433,766                             |
| <b>NET CURRENT ASSETS</b>                                              |    | 20,657                                    | 2,969,602                              |
| <b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>                           |    | 57,574,334                                | 58,628,993                             |

|                                             |    | 30 June<br>2020<br>RMB'000<br>(Unaudited) | 31 December<br>2019<br>RMB'000<br>(Audited) |
|---------------------------------------------|----|-------------------------------------------|---------------------------------------------|
| <b>NON-CURRENT LIABILITIES</b>              |    |                                           |                                             |
| Long-term bank borrowings                   | 16 | 10,953,518                                | 12,576,907                                  |
| Long-term payables                          |    | 369,340                                   | 410,188                                     |
| Deferred income                             |    | 2,928,227                                 | 2,994,048                                   |
| Deferred income                             |    | 417,091                                   | 417,345                                     |
| Long-term payables                          |    | 2,891,682                                 | 2,860,170                                   |
| Long-term payables                          |    | 215,655                                   | 223,009                                     |
|                                             |    | 17,775,513                                | 19,481,667                                  |
| <b>Net assets</b>                           |    | <b>39,798,821</b>                         | <b>39,147,326</b>                           |
| <b>EQUITY</b>                               |    |                                           |                                             |
| Equity attributable to owners of the parent |    |                                           |                                             |
| Share capital                               |    | 2,562,899                                 | 2,562,899                                   |
| Reserves                                    |    | 30,419,792                                | 29,268,280                                  |
|                                             |    | 32,982,691                                | 31,831,179                                  |
| <b>Non-controlling interests</b>            |    | <b>6,816,130</b>                          | <b>7,316,147</b>                            |
| <b>Total equity</b>                         |    | <b>39,798,821</b>                         | <b>39,147,326</b>                           |

Chen Qiyu

Wu Yifang

# Interim Condensed Consolidated

## Statement of Financial Position

For the six months ended 30 June 2020

|                                                        | Attributable to owners of the parent |                          |                               |                                      |                          |                                         |                             | Non-controlling interests | Total equity |
|--------------------------------------------------------|--------------------------------------|--------------------------|-------------------------------|--------------------------------------|--------------------------|-----------------------------------------|-----------------------------|---------------------------|--------------|
|                                                        | Share capital<br>RMB'000             | Share premium<br>RMB'000 | Fair value reserve<br>RMB'000 | Statutory surplus reserve<br>RMB'000 | Other reserve<br>RMB'000 | Exchange fluctuation reserve<br>RMB'000 | Retained profits<br>RMB'000 |                           |              |
| At 1 January 2020 (Audited)                            | 2,562,899                            | 11,385,162*              | (35,546)*                     | 2,523,799*                           | 899,356*                 | (420,878)*                              | 14,916,387*                 | 7,316,147                 | 39,147,326   |
| Effect of the adoption of the new accounting standards | —                                    | —                        | —                             | —                                    | —                        | —                                       | 1,714,710                   | 194,897                   | 1,909,607    |
| Effect of the adoption of the new accounting standards | —                                    | —                        | 3,819                         | —                                    | —                        | —                                       | —                           | (68)                      | 3,751        |
| Effect of the adoption of the new accounting standards | —                                    | —                        | 96,891                        | —                                    | —                        | —                                       | —                           | —                         | 96,891       |
| Effect of the adoption of the new accounting standards | —                                    | —                        | —                             | —                                    | —                        | (154,873)                               | —                           | (100,736)                 | (255,609)    |
| At 30 June 2020 (Unaudited)                            | —                                    | —                        | 100,710                       | —                                    | —                        | (154,873)                               | 1,714,710                   | 94,093                    | 1,754,640    |
| At 30 June 2019 (Audited)                              | —                                    | —                        | —                             | —                                    | 159,607                  | —                                       | —                           | (521,291)                 | (361,684)    |
| At 30 June 2018 (Audited)                              | —                                    | —                        | —                             | —                                    | (784)                    | —                                       | —                           | 62                        | (722)        |
| At 30 June 2017 (Audited)                              | —                                    | —                        | —                             | —                                    | (2,433)                  | —                                       | —                           | —                         | (2,433)      |
| At 30 June 2016 (Audited)                              | —                                    | —                        | —                             | —                                    | —                        | —                                       | —                           | 56                        | 56           |
| At 30 June 2015 (Audited)                              | —                                    | —                        | —                             | —                                    | —                        | —                                       | —                           | 24,495                    | 24,495       |
| At 30 June 2014 (Audited)                              | —                                    | —                        | —                             | —                                    | —                        | —                                       | —                           | (241,721)                 | (241,721)    |
| At 30 June 2013 (Audited)                              | —                                    | —                        | —                             | —                                    | —                        | —                                       | —                           | 162,645                   | 162,645      |
| At 30 June 2012 (Audited)                              | —                                    | —                        | —                             | —                                    | 5,346                    | —                                       | —                           | (18,356)                  | (13,010)     |
| At 30 June 2011 (Audited)                              | —                                    | —                        | —                             | —                                    | 329,734                  | —                                       | —                           | —                         | 329,734      |
| At 30 June 2010 (Audited)                              | —                                    | —                        | —                             | —                                    | —                        | —                                       | (1,000,505)                 | —                         | (1,000,505)  |
| At 30 June 2009 (Audited)                              | —                                    | —                        | —                             | —                                    | —                        | —                                       | —                           | —                         | —            |
| At 30 June 2008 (Audited)                              | —                                    | —                        | 107,320                       | —                                    | —                        | —                                       | (107,320)                   | —                         | —            |
| At 30 June 2020 (Unaudited)                            | 2,562,899                            | 11,385,162*              | 172,484*                      | 2,523,799*                           | 1,390,826*               | (575,751)*                              | 15,523,272*                 | 6,816,130                 | 39,798,821   |

\* Represents the amount of the share premium account in the consolidated financial statements of the Group as at 30 June 2020, which is the same as the amount of the share premium account in the consolidated financial statements of the Group as at 30 June 2019: RMB30,419,792,000 (31 December 2019: RMB29,268,280,000).

# Interim Condensed Consolidated

Statement of Cash Flows

in millions of dollars for the periods ended

30

2020

|                                     | Assets         |                    |                     |                         |            |                |                    |                     |                         |           |                |       |
|-------------------------------------|----------------|--------------------|---------------------|-------------------------|------------|----------------|--------------------|---------------------|-------------------------|-----------|----------------|-------|
|                                     | Current assets | Non-current assets | Current liabilities | Non-current liabilities | Equity     | Current assets | Non-current assets | Current liabilities | Non-current liabilities | Equity    | Current assets |       |
|                                     | B'000          | B'000              | B'000               | B'000                   | B'000      | B'000          | B'000              | B'000               | B'000                   | B'000     | B'000          | B'000 |
| A 1 a a 2019 (A )                   | 2,563,061      | 11,386,711*        | (1,711)             | 30,105*                 | 2,374,998* | (701,196)*     | (293,315)*         | 12,562,197*         | 27,920,850              | 5,614,977 | 33,535,827     |       |
| Change in cash and cash equivalents |                |                    |                     |                         |            |                |                    | 1,516,120           | 1,516,120               | 303,509   | 1,819,629      |       |
| Operating activities                |                |                    |                     |                         |            |                |                    |                     |                         |           |                |       |
| Change in cash and cash equivalents |                |                    |                     | (26,838)                |            |                |                    | (26,838)            |                         | 14        | (26,824)       |       |
| Investing activities                |                |                    |                     | (30,026)                |            |                |                    | (30,026)            |                         |           | (30,026)       |       |
| Financing activities                |                |                    |                     |                         |            |                | 85,667             |                     | 85,667                  | 15,158    | 100,825        |       |
| Change in cash and cash equivalents |                |                    |                     | (56,864)                |            |                | 85,667             | 1,516,120           | 1,544,923               | 318,681   | 1,863,604      |       |
| A 2 a a 2020 (A )                   |                |                    |                     |                         |            | (81,915)       |                    | (81,915)            |                         | (9,499)   | (91,414)       |       |
| Change in cash and cash equivalents |                |                    |                     | (162)                   | (1,549)    | 1,711          |                    |                     |                         | 23,284    | 23,284         |       |
| Operating activities                |                |                    |                     |                         |            |                |                    |                     |                         |           |                |       |
| Change in cash and cash equivalents |                |                    |                     |                         |            | 1,129          |                    | 1,129               |                         | (1,129)   |                |       |
| Investing activities                |                |                    |                     |                         |            | (2,214)        |                    | (2,214)             |                         |           | (2,214)        |       |
| Financing activities                |                |                    |                     |                         |            | (1,000)        |                    | 1,000               |                         |           |                |       |
| Change in cash and cash equivalents |                |                    |                     |                         |            | (314)          |                    | 314                 |                         | (662)     | (662)          |       |
| Operating activities                |                |                    |                     |                         |            |                |                    |                     |                         | 31,290    | 31,290         |       |
| Investing activities                |                |                    |                     |                         |            |                |                    |                     |                         | (170,553) | (170,553)      |       |
| Financing activities                |                |                    |                     |                         |            |                |                    |                     |                         | 61,867    | 61,867         |       |
| Change in cash and cash equivalents |                |                    |                     |                         |            |                |                    |                     |                         |           |                |       |
| Operating activities                |                |                    |                     |                         |            |                |                    |                     |                         |           |                |       |
| Change in cash and cash equivalents |                |                    |                     |                         |            | 39,361         |                    | 39,361              |                         | (86,121)  | (46,760)       |       |
| Investing activities                |                |                    |                     |                         |            |                |                    |                     |                         |           |                |       |
| Financing activities                |                |                    |                     |                         |            | 67,968         |                    | 67,968              |                         | 6,876     | 74,844         |       |
| Change in cash and cash equivalents |                |                    |                     |                         |            |                |                    | (818,627)           | (818,627)               |           | (818,627)      |       |
| A 30 2019 (A )                      | 2,562,899      | 11,385,162*        |                     | (26,759)*               | 2,373,684* | (676,867)*     | (207,648)*         | 13,261,004*         | 28,671,475              | 5,789,011 | 34,460,486     |       |

\* Represents the amount of cash and cash equivalents at the end of the period. B26,108,576,000 (31 D m 2018: B25,359,500,000)



# Interim Condensed Consolidated

## Statement of Cash Flows

For the six months ended 30 June 2020

|                                                          |    | For the six months ended 30 June |             |
|----------------------------------------------------------|----|----------------------------------|-------------|
|                                                          |    | 2020                             | 2019        |
|                                                          |    | RMB'000                          | B'000       |
|                                                          |    | (Unaudited)                      | (Unaudited) |
| Cash and cash equivalents at the beginning of the period |    | 1,928,625                        | 1,849,335   |
| Less: Cash and cash equivalents at the end of the period |    | (467,328)                        | (399,147)   |
| Net cash and cash equivalents                            |    | 1,461,297                        | 1,450,188   |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES</b>              |    |                                  |             |
| ✓ Purchase of property, plant and equipment              |    | (1,904,148)                      | (2,040,985) |
| A                                                        | 17 | (8,400)                          | (133,162)   |
| ✓ Purchase of intangible assets                          |    | (192,431)                        | (174,524)   |
| ✓ Purchase of financial assets                           |    | (435,607)                        | (109,283)   |
| D                                                        |    | 151,917                          | 35,418      |
| D                                                        |    | 474,449                          | 642,245     |
| D                                                        |    | —                                | 2,296       |
| D                                                        |    | 67,961                           | 41,866      |
| D                                                        |    | —                                | 1,039       |
| D                                                        |    | 18,718                           | 20,053      |
| D                                                        |    | 1,708                            | —           |
| ✓ Purchase of financial assets                           |    | 5,439                            | 26,015      |
| ✓ Purchase of financial assets                           |    | 50,228                           | —           |
| ( )/                                                     |    | (570,138)                        | 570,562     |
| m                                                        |    | (38,629)                         | 39,801      |
| Net cash and cash equivalents                            |    | (2,378,933)                      | (1,078,659) |

# Interim Condensed Consolidated

Statement of Cash Flows

March 30, 2020

# Notes to Interim Condensed Consolidated Statement of Financial Position

30 June 2020

## 1. CORPORATE AND GROUP INFORMATION

The Company is a public company incorporated in the State of New York, USA, under the laws of the State of New York. The Company's principal executive offices are located at 100 West 30th Street, 10th Floor, New York, NY 10018. The Company's telephone number is (212) 850-1000. The Company's website is [www.10xgen.com](http://www.10xgen.com). The Company's fiscal year ends on December 31. The Company's stock is listed on the New York Stock Exchange under the symbol "10X".

The Company is a holding company and its subsidiaries are 10x Genomics, Inc. ("10x Genomics"), 10x Genomics Limited ("10x Genomics Limited"), 10x Genomics (UK) Limited ("10x Genomics (UK) Limited"), 10x Genomics (Australia) Pty Ltd ("10x Genomics (Australia) Pty Ltd"), 10x Genomics (Canada) Inc. ("10x Genomics (Canada) Inc."), 10x Genomics (Japan) K.K. ("10x Genomics (Japan) K.K."), 10x Genomics (Singapore) Pte. Ltd. ("10x Genomics (Singapore) Pte. Ltd."), 10x Genomics (South Korea) Co., Ltd. ("10x Genomics (South Korea) Co., Ltd."), 10x Genomics (Taiwan) Co., Ltd. ("10x Genomics (Taiwan) Co., Ltd."), 10x Genomics (Thailand) Co., Ltd. ("10x Genomics (Thailand) Co., Ltd."), 10x Genomics (Vietnam) Co., Ltd. ("10x Genomics (Vietnam) Co., Ltd."), 10x Genomics (India) Private Limited ("10x Genomics (India) Private Limited"), 10x Genomics (Brazil) Ltda. ("10x Genomics (Brazil) Ltda."), 10x Genomics (Mexico) S de RL de CV ("10x Genomics (Mexico) S de RL de CV"), 10x Genomics (Colombia) S de RL de CV ("10x Genomics (Colombia) S de RL de CV"), 10x Genomics (Chile) S de RL de CV ("10x Genomics (Chile) S de RL de CV"), 10x Genomics (Peru) S de RL de CV ("10x Genomics (Peru) S de RL de CV"), 10x Genomics (Argentina) S de RL de CV ("10x Genomics (Argentina) S de RL de CV"), 10x Genomics (Uruguay) S de RL de CV ("10x Genomics (Uruguay) S de RL de CV"), 10x Genomics (Venezuela) S de RL de CV ("10x Genomics (Venezuela) S de RL de CV"), 10x Genomics (Ecuador) S de RL de CV ("10x Genomics (Ecuador) S de RL de CV"), 10x Genomics (Bolivia) S de RL de CV ("10x Genomics (Bolivia) S de RL de CV"), 10x Genomics (Paraguay) S de RL de CV ("10x Genomics (Paraguay) S de RL de CV"), 10x Genomics (Nicaragua) S de RL de CV ("10x Genomics (Nicaragua) S de RL de CV"), 10x Genomics (Costa Rica) S de RL de CV ("10x Genomics (Costa Rica) S de RL de CV"), 10x Genomics (Panama) S de RL de CV ("10x Genomics (Panama) S de RL de CV"), 10x Genomics (Honduras) S de RL de CV ("10x Genomics (Honduras) S de RL de CV"), 10x Genomics (Guatemala) S de RL de CV ("10x Genomics (Guatemala) S de RL de CV"), 10x Genomics (El Salvador) S de RL de CV ("10x Genomics (El Salvador) S de RL de CV"), 10x Genomics (Belize) S de RL de CV ("10x Genomics (Belize) S de RL de CV"), 10x Genomics (Jamaica) S de RL de CV ("10x Genomics (Jamaica) S de RL de CV"), 10x Genomics (Trinidad and Tobago) S de RL de CV ("10x Genomics (Trinidad and Tobago) S de RL de CV"), 10x Genomics (Suriname) S de RL de CV ("10x Genomics (Suriname) S de RL de CV"), 10x Genomics (Guyana) S de RL de CV ("10x Genomics (Guyana) S de RL de CV"), 10x Genomics (French Guiana) S de RL de CV ("10x Genomics (French Guiana) S de RL de CV"), 10x Genomics (Martinique) S de RL de CV ("10x Genomics (Martinique) S de RL de CV"), 10x Genomics (Guadeloupe) S de RL de CV ("10x Genomics (Guadeloupe) S de RL de CV"), 10x Genomics (Reunion) S de RL de CV ("10x Genomics (Reunion) S de RL de CV"), 10x Genomics (Mayotte) S de RL de CV ("10x Genomics (Mayotte) S de RL de CV"), 10x Genomics (French Polynesia) S de RL de CV ("10x Genomics (French Polynesia) S de RL de CV"), 10x Genomics (New Caledonia) S de RL de CV ("10x Genomics (New Caledonia) S de RL de CV"), 10x Genomics (Wallis and Futuna) S de RL de CV ("10x Genomics (Wallis and Futuna) S de RL de CV"), 10x Genomics (Tokelau) S de RL de CV ("10x Genomics (Tokelau) S de RL de CV"), 10x Genomics (Niue) S de RL de CV ("10x Genomics (Niue) S de RL de CV"), 10x Genomics (Cook Islands) S de RL de CV ("10x Genomics (Cook Islands) S de RL de CV"), 10x Genomics (Tonga) S de RL de CV ("10x Genomics (Tonga) S de RL de CV"), 10x Genomics (Samoa) S de RL de CV ("10x Genomics (Samoa) S de RL de CV"), 10x Genomics (Tahiti) S de RL de CV ("10x Genomics (Tahiti) S de RL de CV"), 10x Genomics (French Polynesia) S de RL de CV ("10x Genomics (French Polynesia) S de RL de CV"), 10x Genomics (New Caledonia) S de RL de CV ("10x Genomics (New Caledonia) S de RL de CV"), 10x Genomics (Wallis and Futuna) S de RL de CV ("10x Genomics (Wallis and Futuna) S de RL de CV"), 10x Genomics (Tokelau) S de RL de CV ("10x Genomics (Tokelau) S de RL de CV"), 10x Genomics (Niue) S de RL de CV ("10x Genomics (Niue) S de RL de CV"), 10x Genomics (Cook Islands) S de RL de CV ("10x Genomics (Cook Islands) S de RL de CV"), 10x Genomics (Tonga) S de RL de CV ("10x Genomics (Tonga) S de RL de CV"), 10x Genomics (Samoa) S de RL de CV ("10x Genomics (Samoa) S de RL de CV"), 10x Genomics (Tahiti) S de RL de CV ("10x Genomics (Tahiti) S de RL de CV").

## 2. BASIS OF PREPARATION

The interim condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America ("GAAP") for interim financial information. The financial statements are unaudited and should be read in conjunction with the audited financial statements for the year ended December 31, 2019.

## 3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Company has adopted Accounting Standards Update ("ASU") 2016-01, "Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments," effective January 1, 2020. The adoption of this ASU resulted in a change in the Company's accounting policy for the measurement of credit losses on financial instruments. The Company's policy was to measure credit losses on financial instruments using the incurred loss method. The Company's new policy is to measure credit losses on financial instruments using the expected credit loss method. The adoption of this ASU resulted in a change in the Company's accounting policy for the measurement of credit losses on financial instruments. The Company's new policy is to measure credit losses on financial instruments using the expected credit loss method. The adoption of this ASU resulted in a change in the Company's accounting policy for the measurement of credit losses on financial instruments. The Company's new policy is to measure credit losses on financial instruments using the expected credit loss method.

a a s a m

### 3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

(a) Am m s 3 a a a a a . am m a a a  
a a a a , m , a am m m, a a a a  
a a a a . A a a a  
a a . am m m a m ma a a a a a  
a a a , a a a a a a  
a a a . am m a a a  
m , am m a a a a a m m a a  
a a a m a m a a a a a a a a  
a a am m a a a a a a 1 a a 2020.  
am m a a ma a a a

( ) Am m 5 16 a a a -19 a m . a a m a a  
a a -19 a m a ( ) a a a m  
a a a a a a a a , a a mm a  
a ; ( ) a a a m a m a 30 2021; a ( )  
a a m a a . am m a a  
a 1 2020 a a a m .

D

30 2020, a m a a m a a , a

a a a -19 a m a a a a m a a .

a a a am m 1 a a 2020 a a a m a a a

a a a -19 a m 30 2020. A , a

a a m a m B4,787,000.00 a a a a a a m

a a a a a 30 2020.

( ) Am m AS 1 a AS 8 a ma a. a a ma ma a  
m , m a a a  
a a a m ma a a a a m . am m a a ma a  
a ma ma . am m a a m a ' m a  
a a ma .

## 4. OPERATING SEGMENT INFORMATION

|        |              |            |               |                 |     |          |        |
|--------|--------------|------------|---------------|-----------------|-----|----------|--------|
|        | ma a m       | ,          | a             | a               | a   | a a      | a      |
|        | a m a        | :          |               |                 |     |          |        |
| (a)    | a ma         | a ma a     | a &D m ma     | a               | ,   | a a      | a ma a |
|        |              |            |               |                 |     |          |        |
| ( )    | m a          | a m a a    | m ma          | a               | a a | m a      | a a    |
|        |              |            |               |                 |     |          |        |
| ( )    | a a          | m ma       | a             | a a             | a   | a ma a m |        |
|        |              |            |               |                 |     |          |        |
| ( )    | a ma         | a          | a a m ma      | a               | a a | a a ma a |        |
|        |              |            |               |                 |     |          |        |
| ( )    |              | a m m      | a m           | a               |     |          |        |
|        |              |            |               |                 |     |          |        |
| ▼▼     | a a m m      |            | a m           | a a             | ma  | a        |        |
|        | a a a        | ma a m     | .S m          | ma a a a        | a m | ,        | a m a  |
|        | a            | a a.       | a             | a a ma          |     |          | a a    |
|        | a            | m m a a a  | a a a         | a               | m   | a a a a  |        |
|        | m            | m,         | a             | a a a a a a a   |     | a a a    |        |
|        | a a a a a a  |            | a a a a a a a | m ma a m        |     | m a      | a      |
|        | m            | ma m       |               |                 |     |          |        |
|        |              |            |               |                 |     |          |        |
|        | m            | a m a      | a             | m a a a a a a a |     |          |        |
|        | a ma         | a a        | a ma          |                 |     |          |        |
|        |              |            |               |                 |     |          |        |
| S m a  | a a a a a a  |            | m             | a a a a         |     |          |        |
| m      | m a a a a    | a m ma a m | a a           | a a ma a        |     |          |        |
|        | a            |            |               |                 |     |          |        |
|        |              |            |               |                 |     |          |        |
| S m a  | - a a a      |            | a a a a a a   | a a m           |     |          |        |
| ma a m | a a a a ma a | a          | a             |                 |     |          |        |

# Notes to Interim Condensed Consolidated

a a s a m

30 2020

## 4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2020 (unaudited)

|                                   | Pharmaceutical<br>manufacturing<br>and R&D<br>RMB'000 | Medical<br>devices<br>and medical<br>diagnosis<br>RMB'000 | Healthcare<br>Service<br>RMB'000 | Pharmaceutical<br>distribution<br>and retail<br>RMB'000 | Other<br>business<br>operations<br>RMB'000 | Adjustments<br>and<br>Eliminations<br>RMB'000 | Total<br>RMB'000 |
|-----------------------------------|-------------------------------------------------------|-----------------------------------------------------------|----------------------------------|---------------------------------------------------------|--------------------------------------------|-----------------------------------------------|------------------|
| <b>Segment revenue:</b>           |                                                       |                                                           |                                  |                                                         |                                            |                                               |                  |
| S a a m                           | 9,952,096                                             | 2,638,887                                                 | 1,359,017                        | —                                                       | 15,179                                     | —                                             | 13,965,179       |
| m a                               | 48,294                                                | 46,610                                                    | 4,700                            | —                                                       | 8,270                                      | (107,874)                                     | —                |
| a                                 | 10,000,390                                            | 2,685,497                                                 | 1,363,717                        | —                                                       | 23,449                                     | (107,874)                                     | 13,965,179       |
| <b>Segment results*</b>           |                                                       |                                                           |                                  |                                                         |                                            |                                               |                  |
| m                                 | 1,115,513                                             | 509,746                                                   | 31,373                           | —                                                       | (4,289)                                    | (19,026)                                      | 1,633,317        |
| a                                 | 135,673                                               | 10,551                                                    | 16,910                           | —                                                       | 16,579                                     | —                                             | 179,713          |
| m                                 | 157,704                                               | 14,210                                                    | 3,393                            | —                                                       | 275,233                                    | 30                                            | 450,570          |
| a                                 | 56,129                                                | 10,345                                                    | 17,531                           | —                                                       | 185                                        | (5,291)                                       | 78,899           |
| a                                 | (51,353)                                              | (14,125)                                                  | (17,409)                         | —                                                       | (5,587)                                    | 26,170                                        | (62,304)         |
| a                                 | 27,605                                                | (55,433)                                                  | (6,267)                          | —                                                       | (22,062)                                   | —                                             | (56,157)         |
| S a a :                           | (45,744)                                              | —                                                         | —                                | —                                                       | (814)                                      | —                                             | (46,558)         |
| A a                               | 32,681                                                | 24,021                                                    | (31,134)                         | 724,041                                                 | (50,645)                                   | —                                             | 698,964          |
| L a a m , m                       |                                                       |                                                           |                                  |                                                         |                                            |                                               | 171,305          |
| L a a                             |                                                       |                                                           |                                  |                                                         |                                            |                                               | (365,574)        |
| L a a                             |                                                       |                                                           |                                  |                                                         |                                            |                                               | (380,487)        |
| a                                 | 1,428,208                                             | 499,315                                                   | 14,397                           | 724,041                                                 | 208,600                                    | 1,883                                         | 2,301,688        |
| a                                 | (313,433)                                             | (65,625)                                                  | (12,784)                         | —                                                       | (239)                                      | —                                             | (392,081)        |
| a                                 | 1,114,775                                             | 433,690                                                   | 1,613                            | 724,041                                                 | 208,361                                    | 1,883                                         | 1,909,607        |
| <b>Segment assets:</b>            |                                                       |                                                           |                                  |                                                         |                                            |                                               |                  |
| a                                 | 41,047,332                                            | 8,262,367                                                 | 9,812,781                        | 13,877,770                                              | 4,251,314                                  | (1,683,155)                                   | 75,568,409       |
| m                                 | 349,474                                               | —                                                         | —                                | —                                                       | 6,730                                      | —                                             | 356,204          |
| L a a a                           | 2,248,581                                             | 1,102,609                                                 | 1,624,283                        | 13,877,770                                              | 2,859,201                                  | —                                             | 21,712,444       |
| L a a a                           |                                                       |                                                           |                                  |                                                         |                                            |                                               | 4,544,467        |
| a a                               |                                                       |                                                           |                                  |                                                         |                                            |                                               | 80,112,876       |
| <b>Segment liabilities:</b>       |                                                       |                                                           |                                  |                                                         |                                            |                                               |                  |
| L a a a                           | 18,654,179                                            | 1,937,780                                                 | 2,229,824                        | —                                                       | 386,141                                    | (9,370,028)                                   | 13,837,896       |
| L a a a                           |                                                       |                                                           |                                  |                                                         |                                            |                                               | 26,476,159       |
| a a                               |                                                       |                                                           |                                  |                                                         |                                            |                                               | 40,314,055       |
| <b>Other segment information:</b> |                                                       |                                                           |                                  |                                                         |                                            |                                               |                  |
| D a a a m a                       | 590,999                                               | 96,170                                                    | 133,901                          | —                                                       | 15,197                                     | —                                             | 836,267          |
| m a m                             | (32,251)                                              | 49,686                                                    | 2,365                            | —                                                       | 22,048                                     | —                                             | 41,848           |
| C a a **                          | 1,309,447                                             | 97,984                                                    | 356,886                          | —                                                       | 47,953                                     | —                                             | 1,812,270        |

\* S m a a a m a , a , a m a a a a

\*\* C a a a a a m , a a a a a a a a a a

# Notes to Interim Condensed Consolidated

a a s a m

30 June 2020

## 4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2019 (unaudited)

|                                   | ma a<br>a a<br>B'000 | a m a<br>a a<br>B'000 | a a<br>s<br>B'000 | a a<br>B'000 | a<br>B'000 | A m<br>m a<br>B'000 | a<br>B'000 |
|-----------------------------------|----------------------|-----------------------|-------------------|--------------|------------|---------------------|------------|
| <b>Segment revenue:</b>           |                      |                       |                   |              |            |                     |            |
| S a a m                           | 10,814,123           | 1,792,865             | 1,458,512         |              | 19,646     |                     | 14,085,146 |
| m a                               | 8,421                | 19,401                | 1,876             |              | 20,674     | (50,372)            |            |
| a                                 | 10,822,544           | 1,812,266             | 1,460,388         |              | 40,320     | (50,372)            | 14,085,146 |
| <b>Segment results*</b>           |                      |                       |                   |              |            |                     |            |
| m                                 | 1,204,721            | 291,795               | 168,982           |              | 10,328     | (19,887)            | 1,655,939  |
| a                                 | 75,540               | 13,034                | 3,681             |              | 3,326      |                     | 95,581     |
| m                                 | 281,499              | (3,481)               | (748)             | 7,274        | 2,679      |                     | 287,223    |
| a                                 | 50,628               | 16,153                | 21,874            |              | 216        | (1,236)             | 87,635     |
| a                                 | (56,712)             | (9,467)               | (12,032)          |              | (6,320)    | 29,102              | (55,429)   |
|                                   | (15,616)             | (22,095)              | (15,446)          |              | 1,121      |                     | (52,036)   |
| S a a :                           | (25,565)             | 477                   |                   |              | (845)      |                     | (25,933)   |
| A a                               | 37,529               | (25,330)              | (13,655)          | 774,939      | (13,428)   |                     | 760,055    |
| a a m , m                         |                      |                       |                   |              |            |                     | 115,621    |
| a a                               |                      |                       |                   |              |            |                     | (491,511)  |
| a a                               |                      |                       |                   |              |            |                     | (180,995)  |
| a                                 | 1,552,024            | 261,086               | 152,656           | 782,213      | (2,923)    | 7,979               | 2,196,150  |
| a a a                             | (319,655)            | (30,673)              | (51,774)          |              | (258)      |                     | (402,360)  |
| a a a                             |                      |                       |                   |              |            |                     | 25,839     |
| a                                 | 1,232,369            | 230,413               | 100,882           | 782,213      | (3,181)    | 7,979               | 1,819,629  |
| <b>Segment assets:</b>            | 36,425,494           | 6,874,258             | 10,781,464        | 12,429,996   | 4,362,843  | (1,490,584)         | 69,383,471 |
| a                                 | 399,018              | 12,808                |                   |              | 9,134      |                     | 420,960    |
| a a a                             | 2,153,707            | 948,143               | 3,232,275         | 12,429,996   | 3,085,411  |                     | 21,849,532 |
| a a a                             |                      |                       |                   |              |            |                     | 4,249,250  |
| a a                               |                      |                       |                   |              |            |                     | 73,632,721 |
| <b>Segment liabilities:</b>       | 15,346,659           | 1,505,277             | 1,698,142         |              | 281,002    | (8,590,276)         | 10,240,804 |
| a a a                             |                      |                       |                   |              |            |                     | 28,931,431 |
| a a                               |                      |                       |                   |              |            |                     | 39,172,235 |
| <b>Other segment information:</b> |                      |                       |                   |              |            |                     |            |
| D a a a m a                       | 502,504              | 85,220                | 133,338           |              | 19,190     |                     | 740,252    |
| m a m                             |                      |                       |                   |              |            |                     |            |
| a m                               | 2,435                | 19,425                | 6,493             |              | (2,198)    |                     | 26,155     |
| Ca a **                           | 1,016,436            | 85,165                | 160,766           |              | 95,489     |                     | 1,357,856  |

\* S m a a a m a , a , a m a a a a

\*\* Ca a a a a a m , a a a a a a m - a ( a m a a ).

Notes to Interim Condensed Consolidated

Financial Statements

30 June 2020

5. REVENUE

Revenue is derived from:

|                                       | For the six months ended 30 June |             |
|---------------------------------------|----------------------------------|-------------|
|                                       | 2020                             | 2019        |
|                                       | RMB'000                          | RMB'000     |
|                                       | (Unaudited)                      | (Unaudited) |
| Revenue from contracts with customers | 13,951,418                       | 14,066,560  |
| Revenue from other sources            | 13,761                           | 18,586      |
|                                       | 13,965,179                       | 14,085,146  |



# Notes to Interim Condensed Consolidated

a a s a m

30 June 2020

## 5. REVENUE (Continued)

For the six months ended 30 June 2019 (unaudited)

|                                                | Revenue           | Cost of sales    | Gross profit     | Research and development | Net revenue       |
|------------------------------------------------|-------------------|------------------|------------------|--------------------------|-------------------|
|                                                | B'000             | B'000            | B'000            | B'000                    | B'000             |
| <b>Types of goods or services</b>              |                   |                  |                  |                          |                   |
| Sales                                          | 10,564,090        | 1,671,542        | 27,181           |                          | 12,262,813        |
| Cost of sales                                  | 238,771           | 111,402          | 1,430,327        | 2,144                    | 1,782,644         |
| Sales minus cost of sales                      | 11,182            | 9,921            |                  |                          | 21,103            |
| <b>Geographical markets</b>                    |                   |                  |                  |                          |                   |
| Asia Pacific                                   | 8,288,825         | 1,024,242        | 1,457,508        | 406                      | 10,770,981        |
| Other                                          | 2,525,218         | 768,623          |                  | 1,738                    | 3,295,579         |
| <b>Timing of revenue recognition</b>           |                   |                  |                  |                          |                   |
| Short-term contracts                           | 10,575,272        | 1,681,463        | 27,181           |                          | 12,283,916        |
| Long-term contracts                            | 128,209           | 41,595           | 1,430,327        | 2,144                    | 1,602,275         |
| Short-term contracts minus long-term contracts | 110,562           | 69,807           |                  |                          | 180,369           |
| <b>Total</b>                                   | <b>10,814,043</b> | <b>1,792,865</b> | <b>1,457,508</b> | <b>2,144</b>             | <b>14,066,560</b> |

## Notes to Interim Condensed Consolidated

a a s a m

30 2020

### 6. OTHER INCOME

|                       |         | For the six months ended 30 June |         |
|-----------------------|---------|----------------------------------|---------|
|                       |         | 2020                             | 2019    |
|                       |         | RMB'000                          | B'000   |
|                       |         | (Unaudited)                      | ( )     |
| D m m a a a a a a a a |         |                                  |         |
|                       | m a a a | 20,391                           | 17,523  |
|                       | m a     | 158,367                          | 92,104  |
|                       | m a     | 1,671                            | 97      |
|                       |         | 180,429                          | 109,724 |

### 7. OTHER GAINS

|                   |                 | For the six months ended 30 June |         |
|-------------------|-----------------|----------------------------------|---------|
|                   |                 | 2020                             | 2019    |
|                   |                 | RMB'000                          | B'000   |
|                   |                 | (Unaudited)                      | ( )     |
| a a a a a a a a a |                 |                                  |         |
|                   | a a a a a a a a | 87,209                           | 27,528  |
|                   | a a a a a a a a | 439,102                          | 327,405 |
|                   | a a a a         | —                                | 2,186   |
|                   |                 | 77,311                           | 32,567  |
|                   |                 | 603,622                          | 389,686 |

### 8. FINANCE COSTS

|             |     | For the six months ended 30 June |         |
|-------------|-----|----------------------------------|---------|
|             |     | 2020                             | 2019    |
|             |     | RMB'000                          | B'000   |
|             |     | (Unaudited)                      | ( )     |
| a a ( a a ) |     |                                  |         |
|             | a a | 425,687                          | 543,161 |
|             | a a | 12,188                           | 12,355  |
|             | a a | (9,997)                          | (8,576) |
|             |     | 427,878                          | 546,940 |

# Notes to Interim Condensed Consolidated

Financial Statements

30 June 2020

## 9. PROFIT BEFORE TAX

The following table shows the components of profit before tax:

|                                                                                 | For the six months ended 30 June |                                |
|---------------------------------------------------------------------------------|----------------------------------|--------------------------------|
|                                                                                 | 2020<br>RMB'000<br>(Unaudited)   | 2019<br>RMB'000<br>(Unaudited) |
| Cost of sales                                                                   | 4,932,900                        | 4,263,438                      |
| Cost of services                                                                | 1,282,972                        | 1,335,545                      |
| Operating expenses (including depreciation, amortisation and impairment losses) | 2,468,297                        | 1,952,209                      |
| Depreciation                                                                    | 66,453                           | 134,290                        |
| Amortisation                                                                    | 83,795                           | 67,904                         |
| Share-based payment                                                             | 39,516                           | 46,956                         |
|                                                                                 | 2,658,061                        | 2,201,359                      |
| Other income:                                                                   |                                  |                                |
| Cost of research and development                                                | 1,167,594                        | 816,188                        |
| Other income                                                                    | 46,028                           | 12,128                         |
|                                                                                 | 1,121,566                        | 804,060                        |
| Other income                                                                    | 12,963                           | 10,981                         |
| Depreciation                                                                    | 490,945                          | 458,599                        |
| Depreciation                                                                    | 91,076                           | 74,916                         |
| Amortisation                                                                    | 254,247                          | 206,737                        |
| (Share-based payment)                                                           | (917)                            | 4,237                          |
| Share-based payment                                                             | 42,765                           | 21,918                         |
| Share-based payment                                                             | (439,102)                        | (327,405)                      |
| Share-based payment                                                             | (69,551)                         | (6,028)                        |
| Share-based payment                                                             | (1,621)                          | (18,465)                       |

\* The share-based payment is measured at fair value at the grant date and is recognised as an expense over the vesting period. The share-based payment is measured at fair value at the grant date and is recognised as an expense over the vesting period.

# Notes to Interim Condensed Consolidated

Financial Statements

30 June 2020

## 10. INCOME TAX

The Company's income tax expense for the six months ended 30 June 2020 is RMB467,327 (2019: RMB464,045). The effective tax rate for the six months ended 30 June 2020 is 25% (2019: 25%).

The Company's income tax expense for the six months ended 30 June 2019 is RMB464,045. The effective tax rate for the six months ended 30 June 2019 is 25%.

The Company's income tax expense for the six months ended 30 June 2020 is RMB467,327 (2019: RMB464,045).

|   | For the six months ended 30 June |                              |
|---|----------------------------------|------------------------------|
|   | 2020<br>RMB'000<br>(Unaudited)   | 2019<br>RMB'000<br>(Audited) |
| C | 467,327                          | 464,045                      |
| D | (75,246)                         | (87,524)                     |
|   | 392,081                          | 376,521                      |

## 11. DIVIDENDS

The Company's dividends for the six months ended 30 June 2020 are RMB0.39 (2019: RMB0.39).

The Company's dividends for the six months ended 30 June 2019 are RMB0.39 (2019: RMB0.39).

a a s a m

## 12. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

a a a a m a a a a a a a a m 51 / 1

a a s a m

### 13. PROPERTY, PLANT AND EQUIPMENT

|    |   |   |    |      |            |
|----|---|---|----|------|------------|
| Ca | a | a | 30 | 2020 | 11,313,846 |
|----|---|---|----|------|------------|

16 B217,305,000 (31 D m 2019: B133,709,000),

|                    | 30 June 2020 | 31 December 2019 |
|--------------------|--------------|------------------|
|                    | RMB'000      | B'000            |
|                    | (Unaudited)  | (Audited)        |
| Operating income   | 5,080,545    | 4,367,600        |
| Operating expenses | 190,943      | 240,122          |
| Operating profit   | 5,271,488    | 4,607,722        |

$\frac{a}{a} = \frac{a}{a} = \frac{a}{a} = m$ ,  $\frac{ma}{m} = \frac{ma}{m} = \frac{a}{a}$

a a s a m

#### 14. TRADE AND BILLS RECEIVABLES (Continued)

## 15. TRADE AND BILLS PAYABLES

|                          | 30 June<br>2020<br>RMB'000<br>(Unaudited) | 31 Dec<br>2019<br>RMB'000<br>(Audited) |
|--------------------------|-------------------------------------------|----------------------------------------|
| Operating income         | 2,566,965                                 | 2,152,747                              |
| Operating expenses       | 297,052                                   | 244,568                                |
| Operating profit         | 2,864,017                                 | 2,397,315                              |
| Other income             | -                                         | -                                      |
| Other expenses           | -                                         | -                                      |
| Profit before income tax | 2,864,017                                 | 2,397,315                              |
| Income tax               | -                                         | -                                      |
| Profit for the period    | 2,864,017                                 | 2,397,315                              |

# Notes to Interim Condensed Consolidated

Financial Statements

30 June 2020

## 16. INTEREST-BEARING BANK AND OTHER BORROWINGS

|                        |     | 30 June<br>2020<br>RMB'000<br>(Unaudited) | 31 December<br>2019<br>RMB'000<br>(Audited) |
|------------------------|-----|-------------------------------------------|---------------------------------------------|
| Bank borrowings:       | (1) | 486,008                                   | 344,186                                     |
| Other borrowings:      |     | 15,096,396                                | 13,762,714                                  |
|                        |     | 15,582,404                                | 14,106,900                                  |
| Short-term borrowings: | (2) | 899,616                                   | -                                           |
| Long-term borrowings:  | (3) | 6,876,099                                 | 7,030,209                                   |
|                        |     | 23,358,119                                | 21,137,109                                  |
| Less: Borrowing costs  |     | (12,404,601)                              | (8,560,202)                                 |
|                        |     | 10,953,518                                | 12,576,907                                  |

At the end of the reporting period, the carrying amounts of the bank and other borrowings are as follows:

|                          |  | 30 June<br>2020<br>RMB'000<br>(Unaudited) | 31 December<br>2019<br>RMB'000<br>(Audited) |
|--------------------------|--|-------------------------------------------|---------------------------------------------|
| Bank borrowings:         |  |                                           |                                             |
| 1. Short-term borrowings |  | 12,404,601                                | 8,560,202                                   |
| 2. Long-term borrowings  |  | 7,833,867                                 | 6,860,077                                   |
| 3. Other borrowings      |  | 2,633,443                                 | 5,395,435                                   |
|                          |  | 486,208                                   | 321,395                                     |
|                          |  | 23,358,119                                | 21,137,109                                  |
| Less: Borrowing costs    |  | (12,404,601)                              | (8,560,202)                                 |
|                          |  | 10,953,518                                | 12,576,907                                  |



a a s a m

## 16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

|   |   |   |   |   |   |   |         |               |   |               |          |   |    |
|---|---|---|---|---|---|---|---------|---------------|---|---------------|----------|---|----|
| a | a | a | a | a | a | m | 0.3000% | 6.2000% (31 D | m | 2019: 0.7500% | 7.5000%) | a | m. |
|---|---|---|---|---|---|---|---------|---------------|---|---------------|----------|---|----|

At 30 June 2020, the Group's net assets were HK\$1,337,709,000 (2019: HK\$1,337,709,000), of which HK\$396,459,000 (2019: HK\$396,459,000) were attributable to the equity holders of the Company.

At 30 June 2020, the Group's net assets were HK\$1,337,709,000 (2019: HK\$1,337,709,000), of which HK\$396,459,000 (2019: HK\$396,459,000) were attributable to the equity holders of the Company.

2020, C m a - m mm a a a a a am B600,000,000, a a 2.50%  
a m. S S - m C mm a a a a ma a a 27 m 2020.

8 A 2020, C m a a - m mm a a a a a am B300,000,000, a  
a 2.20% a m. S S - m C mm a a a a ma a a 7 2020.

[illegible]

a a s a m

## 17. BUSINESS COMBINATION

9. a 2020, \$ a a a a a . a D m C , , a a C m a , a a 51%  
C ( \$ ) a a a C , . ( C ) m a a . a a  
a B5,250,000. A a , 100% C.C.

Fair value  
recognised on  
acquisition

|                                                   | Number of employees | Costs in million euros |
|---------------------------------------------------|---------------------|------------------------|
| Personnel costs:                                  |                     |                        |
| - Salaries and wages                              | 13                  | 14,953                 |
| - Social security contributions                   |                     | 518                    |
| - Other personnel costs                           |                     | 33,774                 |
| - Personnel expenses                              |                     | 11,142                 |
| - Personnel benefits                              |                     | 40,494                 |
| - Cash compensation for termination of employment |                     | 14,529                 |
| - Other cash payments                             |                     | (12,132)               |
| - Cash payments for other reasons                 |                     | (405)                  |
| - Other cash payments                             |                     | (70,779)               |
| Total personnel costs                             |                     | 32,094                 |
| - Personnel costs                                 |                     | (15,944)               |
| Total personnel costs                             |                     | 16,150                 |
| Social security contributions:                    |                     |                        |
| - Contributions                                   |                     | 16,150                 |

▼▼ B9,524,000, . a a a a a a a a am ▼▼ B40,494,000 a

a a s a m

## 17. BUSINESS COMBINATION (Continued)

## 18. COMMITMENTS

|                                   | 30 June<br>2020<br>RMB'000<br>(Unaudited) | 31 Dec<br>2019<br>RMB'000<br>(Audited) |
|-----------------------------------|-------------------------------------------|----------------------------------------|
| Cost of sales                     | 2,316,640                                 | 2,191,767                              |
| Gross profit                      | 880,140                                   | 929,930                                |
| Selling and distribution expenses | 253,149                                   | 273,236                                |
| Administrative expenses           | 4,434,832                                 | 4,285,335                              |
| Finance income                    | 7,884,761                                 | 7,680,268                              |


a a s a m

## 19. RELATED PARTY TRANSACTIONS

## For the six months ended 30 June

2019

B'000



















| Section                                | Count            | Percentage       |
|----------------------------------------|------------------|------------------|
| S a m C . . a a ( 4 & 6 & 15)          | 1,395,932        | 1,567,956        |
| C . . a m a a C . . a a ( 1 & 4 & 16)  | 188,335          | 205,246          |
| . . a a m a a ( 3 & 4 & 10 & 16)       | 98,576           | 216              |
| S a ( ) C . . ( 1 & 4)                 | 92,686           | 49,757           |
| S a a (S a a) C . . ( 1 & 4)           | 68,855           | 42,836           |
| a D'a Da C . . a a ( 4 & )             | 7,036            | 32,492           |
| a C m a . ( 4 & )                      | 4,315            |                  |
| S a a a . m a C . . ( 1 & 4)           | 4,030            | 3,256            |
| S a a D'a a . m C . . ( 1 & 4)         | 2,555            | 1,453            |
| a . a m a C . . ( 1 & 4)               | 1,777            | 22               |
| S a a a a a D m C . . ( 2 & 4 & 17)    | 1,612            | 4,702            |
| S a a a B m a . . ( 1 & 4)             | 1,262            |                  |
| a a C a a ) a m a a ) a a ( 1 & 4 & 6) | 737              | 1,575            |
| S a a a a a a S a D m . ( 2 & 4)       | 406              | 148              |
| a a a . . ( 4 & )                      | 42               |                  |
| S a a B C . . ( 4 & )                  | 16               |                  |
| m a a a m (S a a) C . . ( 4 & 7)       | 16               | 17               |
| B a C . . ( 2 & 4)                     | 14               | 12               |
| S a a m a m a C . . ( 1 & 4)           | 13               | 60               |
| S a C a S a a ( 1 & 4)                 | 3                |                  |
| S a a m a C . . ( 1 & 4)               | —                | 17               |
| S a A a S & C . . ( 1 & 4)             | —                | 1                |
| <b>Total</b>                           | <b>1,868,218</b> | <b>1,909,766</b> |

# Notes to Interim Condensed Consolidated

a a s a m

30 June 2020

## 19. RELATED PARTY TRANSACTIONS (Continued)

### (b) Purchase of pharmaceutical products and services

|                                      | Six months ended 30 June |           |
|--------------------------------------|--------------------------|-----------|
|                                      | 2020                     | 2019      |
|                                      | RMB'000                  | B'000     |
|                                      | (Unaudited)              | (Audited) |
| S a m C ., .a a ( 4 & 6 & 15)        | 128,644                  | 125,937   |
| . a a m a a ( 3 & 4 & 11 & 16)       | 96,578                   | 1,156     |
| a C m a .( 4 & )                     | 87,769                   | 8,899     |
| C . a m a a C ., .a a ( 1 & 4 & 16)  | 2,266                    | 410       |
| S a A a s & C ., .( 1 & 4)           | 1,071                    | 1,164     |
| A s a m a a C ., .( 1 & 4)           | 1,007                    | 2,126     |
| S a a a a D m C ., .( 2 & 4 & 17)    | 907                      | 85        |
| a D'a D a C ., .a a ( 4 & )          | 510                      | 3,352     |
| L a a a ., .( 4 & )                  | 33                       |           |
| S a a a a m a C ., .( 1 & 4)         | 23                       |           |
| S a a a B m a ., .( 1 & 4)           | —                        | 1,318     |
| C C (S ) a m a a C ., .( 1 & 4 & 1 ) | —                        | 1,228     |
|                                      | 318,808                  | 145,675   |

### (c) Leasing and property management services

|                                      | Six months ended 30 June |           |
|--------------------------------------|--------------------------|-----------|
|                                      | 2020                     | 2019      |
|                                      | RMB'000                  | B'000     |
|                                      | (Unaudited)              | (Audited) |
| As lessor                            |                          |           |
| B a a C ., .( 2 & 5)                 | 6,106                    | 5,310     |
| . a a m a a ( 3 & 5 & 12 & 16)       | 3,529                    | 7,895     |
| S a a m a m a C ., .( 1 & 5)         | 733                      |           |
| S a a a a D m C ., .( 2 & 5 & 17)    | 578                      | 325       |
| D . m a a a m (S a a) C ., .( 5 & 7) | 471                      | 454       |
| a a C a a a a ( 1 & 5 & 6)           | 413                      | 131       |
| S a a a a a a a a D m .              |                          |           |
| ( 2 & 5)                             | 216                      |           |
| . S a a a (S a a) C ., .( 1 & 5)     | 145                      | 86        |
| S a C ' a a a ( 1 & 5)               | 65                       |           |
| S a a m a C ., .( 1 & 5)             | —                        | 264       |
|                                      | 12,256                   | 14,465    |

# Notes to Interim Condensed Consolidated

a a s a m

30 2020

## 19. RELATED PARTY TRANSACTIONS (Continued)

### (c) Leasing and property management services (Continued)

|                                         | Six months ended 30 June       |                                |
|-----------------------------------------|--------------------------------|--------------------------------|
|                                         | 2020<br>RMB'000<br>(Unaudited) | 2019<br>RMB'000<br>(Unaudited) |
| <b>As lessee</b>                        |                                |                                |
| Leasing services (Note 3 & 5 & 13 & 16) | 2,952                          | 5,477                          |
| Depreciation (Note 5 & )                | 117                            | 114                            |
| Salaries (Note 5 & )                    | 43                             | 41                             |
| Salaries of B & C, (Note 5 & )          | —                              | 2,500                          |
|                                         | <b>3,112</b>                   | <b>8,132</b>                   |
|                                         |                                |                                |
|                                         | Six months ended 30 June       |                                |
|                                         | 2020<br>RMB'000<br>(Unaudited) | 2019<br>RMB'000<br>(Unaudited) |
| <b>Property management services</b>     |                                |                                |
| Leasing services (Note 3 & 5 & 14 & 16) | 6,904                          | 6,651                          |

### (d) Loans from/to a related parties

C m a a a a m C a m ( a ),  
 a a a a a C m a a a ,  
 , m a a a a C a B a a C m m a m  
 1 a a 2020 a 31 D m 2022. m a m m a a a a  
 a B1,000,000,000. m a m m a a a a a  
 B1,000,000,000.

|                                                                       | Six months ended 30 June       |                                |
|-----------------------------------------------------------------------|--------------------------------|--------------------------------|
|                                                                       | 2020<br>RMB'000<br>(Unaudited) | 2019<br>RMB'000<br>(Unaudited) |
| <b>Maximum daily outstanding balance of deposits in Fosun Finance</b> |                                |                                |
| a C a m ( & 16)                                                       | 979,619                        | 574,422                        |

# Notes to Interim Condensed Consolidated

a a s a m

30 June 2020

## 19. RELATED PARTY TRANSACTIONS (Continued)

### (d) Loans from/to related parties (Continued)

|                                     | 30 June<br>2020<br>RMB'000<br>(Unaudited) | 31 Dec<br>2019<br>RMB'000<br>(A) |
|-------------------------------------|-------------------------------------------|----------------------------------|
| <b>A loan from a related party</b>  |                                           |                                  |
| a C a m ( & 16)                     | 52,274                                    | 38,779                           |
| a C, m ( a ) \a ' ( a a ) m a - a a |                                           | B10,884,000 a a                  |
| a 3%.                               |                                           |                                  |
| S a a a ma a D m C., . a - a a      |                                           | B188,840,000 a a a               |
| 10% a ma a am .                     |                                           |                                  |

|                                 | 30 June<br>2020<br>RMB'000<br>(Unaudited) | 31 Dec<br>2019<br>RMB'000<br>(A) |
|---------------------------------|-------------------------------------------|----------------------------------|
| <b>Loans to related parties</b> |                                           |                                  |
| \a ' ( a a ) m ( 1 & 16)        | 10,884                                    | 10,566                           |
| B a C., . ( 2 & 16)             | 188,840                                   | 188,840                          |
|                                 | 199,724                                   | 199,406                          |

### (e) Interest income from/to related parties

|                            | Six months ended 30 June<br>2020<br>RMB'000<br>(Unaudited) | 2019<br>RMB'000<br>(A) |
|----------------------------|------------------------------------------------------------|------------------------|
| <b>Interest income</b>     |                                                            |                        |
| B a C., . ( 2 & 16)        | 4,706                                                      | 2,002                  |
| a C a m ( & 16)            | 3,358                                                      | 1,845                  |
| \a ' s ( a a ) m ( 1 & 16) | 160                                                        | 154                    |
|                            | 8,224                                                      | 4,001                  |

a a s a m

## 19. RELATED PARTY TRANSACTIONS (Continued)

Ba C a ( B C ), a  
 a ; a ( ) a  
 a 10% a  
 m 3%.

|                  | Six months ended 30 June |       |
|------------------|--------------------------|-------|
|                  | 2020                     | 2019  |
|                  | RMB'000                  | B'000 |
| Interest expense | (Unaudited)              |       |
|                  | 1,058                    | 1,619 |

- (1) a a a .
- (2) a .
- (3) a a a a m , m a m a .
- (4) a a a a mm a m ma / a m / a  
a m a .
- (5) a a m a a m a m a m a m a  
a a a a m a m a .
- (6) a a a a .
- (7) a a .
- (8) a a a a a m , m a m a C m a .
- (9) a a a .
- (10) D , a a m a a a a ma .  
a a m a a s a a ( ) C , , s a a a a m C ,  
s a a a a B , a a (s a a) C , , a C , , a  
a a m C , , s a a a ma C , , s a a a a m  
a a m C , , a m C , , C a a m a a m C , , s a a a a  
ma a m C C , , m a S.Aa .
- (11) D , a m a a a m a a a ma .  
a a m a ( ) C , , s a a a ma C , , s a a  
a a m C , , s a a a a a m C , , a C m C , , a s a a a  
a a m C , , .
- (12) D , a a a m a a a a a  
m a a ( ) C , , a C a a m C , , s a a a a  
m a a m C , , s a a a ma C , , s a a a a ma C , , .
- (13) D , a m a a m a a a a m  
a a s a a s a a m a a a m C , , a C a a a a C , , .



# Notes to Interim Condensed Consolidated

a a s a m

30 June 2020

## 19. RELATED PARTY TRANSACTIONS (Continued)

### (e) Interest income from/to related parties (Continued)

(C )

|      |                                          |                             |     |
|------|------------------------------------------|-----------------------------|-----|
| (14) | D                                        | , m a a m m a a m a a . a a |     |
| (15) | s a m C ., . a m a a s a a m . m , a a a |                             |     |
| (16) | a a a a a a a a a a a C a 14A            |                             | 14A |
| (17) | s a a a a D m C ., . a a                 | 19 a 2020.                  |     |
| (18) | C C (s ) a m a C ., . a a                | 9 a 2020.                   |     |

### (f) Compensation of key management personnel of the Group

|               | Six months ended 30 June       |                          |
|---------------|--------------------------------|--------------------------|
|               | 2020<br>RMB'000<br>(Unaudited) | 2019<br>B'000<br>(B'000) |
| ma a          | 50,051                         | 25,416                   |
| s a a , a a a | 15,410                         | 12,417                   |
| m             | 243                            | 501                      |
|               | 65,704                         | 38,334                   |

### (g) Outstanding balances with related parties

|     |                                                                   |                                                |
|-----|-------------------------------------------------------------------|------------------------------------------------|
| ( ) | A a 30 2020, a a a a m m a m a a a                                | B51,513,000 (31 D m 2019: B4,030,000) a a      |
| ( ) | A a 30 2020, a a a a m a a m a a a                                | B983,814,000 (31 D m 2019: B1,071,384,000) a a |
| ( ) | A a 30 2020, a a m a a a B193,654,000 (31 D m 2019: B212,705,000) |                                                |
| ( ) | A a 30 2020, a a m a m a B3,942,000 (31 D m 2019: B5,526,000)     |                                                |
| ( ) | A a 30 2020, a a a a m a m a a                                    | B118,211,000 (31 D m 2019: B46,027,000) a a    |

Notes to Interim Condensed Consolidated

Financial Statements

30 June 2020

19. RELATED PARTY TRANSACTIONS (Continued)

(g) Outstanding balances with related parties (Continued)

As at 30 June 2020, the amounts due from related parties are as follows:

881,705,000

a a s a m

## 20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

a a            a a a    a a    a            a am    a            m            a    a  
a a            a ,    a a            a a .            m        a a m

ma    a a :

a a a m a m a - a a  
 ma a a m a a a m a  
 a a ma a a a a m a a  
 a a a ma a m a a D a ma a a m  
 a a , a a a m a a , a a a a a  
 a m m , a a a , a a m a a a a

B a mma a a a a m a a 30 2020:

a a a m a a a a 3 ma  
m a a ma

m a m a . a m , a m a a , ma m a  
a a , a a m a m a a m ma a a ,  
a D a m a a a a a m ma a a  
a a m 3.

# Notes to Interim Condensed Consolidated

a a s a m

30 2020

## 20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

### Unobservable inputs for Level 3 liabilities (Continued)

S a a a a a m a - a a  
 a a a a a - m a B2,643,984,000 (31 D m 2019: B2,818,244,000) B. DA  
 ( a B , a , D a a Am a ) a a a 2018, a B. DA \ a  
 a 2019.

### Fair value hierarchy

a a a a m a a a a m :

m a, a, a, a  
 30 2020 ( )

|             | Quoted prices<br>in active<br>markets<br>(Level 1)<br>RMB'000 | Fair value measurement using<br>Significant<br>observable<br>inputs<br>(Level 2)<br>RMB'000 | Significant<br>unobservable<br>inputs<br>(Level 3)<br>RMB'000 | Total<br>RMB'000 |
|-------------|---------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------|------------------|
| m a a a a   | 566                                                           | 849                                                                                         | 59,530                                                        | 60,945           |
| m m         | 1,097,737                                                     | 52,959                                                                                      | 1,694,007                                                     | 2,844,703        |
| a a a a a a | —                                                             | 354,915                                                                                     | —                                                             | 354,915          |
| D m a a a   | 1,098,303                                                     | 408,723                                                                                     | 1,753,537                                                     | 3,260,563        |
| m m         |                                                               |                                                                                             |                                                               |                  |

31 201 ( )

|           | ( 1)<br>B'000 | ( 2)<br>B'000 | ( 3)<br>B'000 | a<br>B'000 |
|-----------|---------------|---------------|---------------|------------|
| a a m a m | 1,554         | 52,909        | 53,246        | 107,709    |
| s a s a   | 561,348       | 52,734        | 1,825,724     | 2,439,806  |
| a a a a a |               | 445,103       |               | 445,103    |
| D m a a a | 562,902       | 550,746       | 1,878,970     | 2,992,618  |
| m m       |               |               |               |            |

# Notes to Interim Condensed Consolidated

a a s a m

30 June 2020

## 20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

### Fair value hierarchy (Continued)

| Financial assets at fair value through profit and loss |  | Equity investments Designated at fair value through other comprehensive income |
|--------------------------------------------------------|--|--------------------------------------------------------------------------------|
| RMB'000 (Unaudited)                                    |  | RMB'000 (Unaudited)                                                            |
| At 1 January 2020                                      |  |                                                                                |
| 1,825,724                                              |  | 53,246                                                                         |
| 118,774                                                |  | —                                                                              |
| —                                                      |  | 6,284                                                                          |
| At 30 June 2020                                        |  |                                                                                |
| 1,694,007                                              |  | 59,530                                                                         |
| At 1 January 2019                                      |  |                                                                                |
| 2,155,293                                              |  | 82,301                                                                         |
| 231,452                                                |  | (29,271)                                                                       |
| At 30 June 2019                                        |  |                                                                                |
| 1,786,569                                              |  | 52,690                                                                         |

# Notes to Interim Condensed Consolidated

Financial Statements

30 June 2020

## 20. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

### Fair value hierarchy (Continued)

As at 30 June 2020 (in RMB'000)

|                | Quoted prices<br>in active<br>markets<br>(Level 1)<br>RMB'000 | Fair value measurement using<br>Significant<br>observable<br>inputs<br>(Level 2)<br>RMB'000 | Significant<br>unobservable<br>inputs<br>(Level 3)<br>RMB'000 | Total<br>RMB'000 |
|----------------|---------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------|------------------|
| Amortised cost | —                                                             | —                                                                                           | 2,643,984                                                     | 2,643,984        |

As at 31 December 2019 (in RMB'000)

|                | Quoted prices<br>in active<br>markets<br>(Level 1)<br>RMB'000 | Fair value measurement using<br>Significant<br>observable<br>inputs<br>(Level 2)<br>RMB'000 | Significant<br>unobservable<br>inputs<br>(Level 3)<br>RMB'000 | Total<br>RMB'000 |
|----------------|---------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------------------------------------------|------------------|
| Amortised cost | —                                                             | —                                                                                           | 209,286                                                       | 209,286          |
| Amortised cost | —                                                             | —                                                                                           | 2,608,958                                                     | 2,608,958        |
|                |                                                               |                                                                                             | 2,818,244                                                     | 2,818,244        |

Management has assessed the fair value of financial instruments and concluded that the fair value is not materially different from the carrying amount.

|                | Six months ended 30 June<br>2020<br>RMB'000<br>(Unaudited) | 2019<br>RMB'000<br>(Audited) |
|----------------|------------------------------------------------------------|------------------------------|
| Amortised cost | 2,818,244                                                  | 2,913,876                    |
| Amortised cost | 35,026                                                     | 46,708                       |
| Discount       | (209,286)                                                  | —                            |
| Amortised cost | 2,643,984                                                  | 2,960,584                    |

During the period, there were no transfers between the fair value hierarchy levels.

# Notes to Interim Condensed Consolidated

a a s a m

30 June 2020

## 21. CONTINGENT LIABILITIES

A a 30 2020 a 31 D m 2019, a a a .

## 22. EVENTS AFTER THE REPORTING PERIOD

A a a a , a a a .

## 23. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

m a a a a m a a a a D 25 A  
2020.

|            |                                                                                                                   |
|------------|-------------------------------------------------------------------------------------------------------------------|
| ...        | ...                                                                                                               |
| AS a ( )   | m a ( ) C m a a m a a B1.00 a , a<br>S a a S a a a B                                                              |
| AS a ( )   | ( ) AS a                                                                                                          |
| A a a      | a a a m C m a                                                                                                     |
| A A A a    | a a a C m a                                                                                                       |
| A a a ma a | A a a ma a C ., .*(錦州奧鴻藥業有限責任公司), a a C m a                                                                       |
| A a a      | C mm a A a a                                                                                                      |
| B a        | a D                                                                                                               |
| B a        | a B a                                                                                                             |
| B a        | B a a AB, a m a S , a a a C m a                                                                                   |
| BS         | BS m , a . a a a m a                                                                                              |
| CA/A       | C A & A                                                                                                           |
| C C        | C a a C a C a a a A 14                                                                                            |
|            | C a a a                                                                                                           |
| C a a      | a C a C a a C m a m *(佛山市禪城區中心醫院有限公司), a -<br>m a a a a a D<br>A m a C a D , a (佛山市禪城區人口和衛生藥品監督管理局), a<br>a C m a |
| C a a      | a C a a a a m C m a m *(佛山市禪怡健康管理有限公司)                                                                            |
| C C (B )   | C C a ma a D m (B ) C ., .*(希米科醫藥技術發展(北京)有限<br>公司)                                                                |
| C C a ma a | C C (S ) a ma a C ., .*(希米科(蘇州)醫藥科技有限公司) (a<br>A (S ) a ma a C ., .*(復星艾迪(蘇州)醫藥科技有限<br>公司)), a a C m a a a        |
| C m a a ma | S a a a ma a ( ) C ., .*(上海復星醫藥(集團)股份有限公司), a<br>m a a C m a , S a a AS a a<br>a a a B a S a a S a a S a a ,      |
| a ( )      | a m a a a C m a ,<br>m a a a , a , a a ,<br>a a a                                                                 |



C5 C

C a S a C mm \* (中國證券監督管理委員會), a a  
a a C a a ma

D ( )

( ) C m a

B DA

a , a , a a am a

S

m , S a a a

S C mm

m a , S a a a C mm C m a

L

a L

S a a ( ) C m a m \* (上海復星高科技(集團)有限公司), a  
- a a a a a  
C m a . a 14A.07(1)

m (復星控股有限公司), a - a  
a a a a C m a

a a a a m (復星國際有限公司), a a a a  
a a a C m a , S  
a (S C : 00656)

a a m (復星國際控股有限公司), a 85.29% a

## Definitions

|          |                                             |                                              |                 |
|----------|---------------------------------------------|----------------------------------------------|-----------------|
| a        | a                                           | / a a C m a m *                              | (岳陽廣濟醫院有限公司), a |
| C m a    |                                             |                                              |                 |
| ↗ a ma   | S ↗ a ma C m a m *                          | (桂林南藥股份有限公司), a                              | C m a           |
| S a ()   | a a () a a a a C m a , a m a a              | B1.00 a , a S a a a                          |                 |
|          | a                                           |                                              |                 |
| S a ()   | () S a                                      |                                              |                 |
| a Ca a a | a Ca a a                                    |                                              |                 |
| a        | S a * (深圳恒生醫院), a                           | a C m a                                      |                 |
| S        | a a S a a                                   |                                              |                 |
|          | S a A m a ↗ C                               |                                              |                 |
| a \$     | a                                           |                                              |                 |
|          | S S a                                       |                                              |                 |
| S a      | S a m                                       |                                              |                 |
| a/a a a  | a/a a . a a a C ., .*                       | (淮安興淮國際醫院有限公司), a                            | a               |
| C m a    |                                             |                                              |                 |
| .        | S a- ▼▼ a (\$ a a) C ., *                   | (直觀復星醫療器械技術(上海)有<br>限公司)a . S a- ( ) C ., .* | (直觀復星(香港)有限公司)  |
| \        | , a . a                                     |                                              |                 |
| a a      | a a                                         |                                              |                 |
| m a      | A m Ca a * (安徽濟民腫瘤醫院), a a -                | (民辦非企業單位)                                    |                 |
|          | a ↗ C, a a C m a                            |                                              |                 |
| ▼▼ C     | ▼▼ C S a a D                                | A 10                                         |                 |
| \A ▼▼    | \a a A a a ▼▼ a .                           |                                              |                 |
| \ ▼▼ A   | \a a ▼▼ a ↗ A m a * (中華人民共和國國家藥品監督管理局), ↗ C |                                              |                 |
|          | m a a                                       |                                              |                 |
| \S       | \a a S a . a m , a . a a a ▼▼ m a           |                                              |                 |
| S        | S a                                         |                                              |                 |
| ↗C       | ↗a C a a                                    |                                              |                 |

|                |                                               |
|----------------|-----------------------------------------------|
| ✓              | ✓                                             |
| ✓ a            | ✓ a                                           |
| ✓ C C a        | ✓ C a, a a s a A m a                          |
|                | ✓ C a a a                                     |
| ✓              | ✓ a a                                         |
| &D             | a a m                                         |
| ✓              | 6-m m 1 a a 2020 30 2020                      |
| ▼▼B            | m , a ✓ C                                     |
| s C            | s a C mm                                      |
| s              | s a a (C a 571 a ), a am ,                    |
|                | m m m m                                       |
| s a a          | s a a B , . * (上海復宏漢霖生物技術股份有限公司), a m a       |
|                | s a a (\$ : 02696) a a a C m a                |
| s a a B a ma a | s a a B a ma a C ., . * (上海復宏漢霖生物製藥有限公司), a a |
|                | C m a                                         |
| s a a          | s a a s a a s a * (《上海證券交易所股票上市規則》)           |
| s a a s a      | s a a s a a * (上海證券交易所)                       |
| a ▼▼ a         | s a a a ▼▼ a D m C ., . * (上海星耀醫學科技發展有限公司),   |
|                | a a C m a a a                                 |
| s a            | s a                                           |
| s a            | a a a a C m a a m a a ▼▼ B1.00 a , m A        |
|                | s a a s a                                     |
| s s a          | s s a a * (深圳證券交易所)                           |
| s a m          | s a m C . * (國藥控股股份有限公司), a m a               |
|                | a ( : 01099)                                  |
| s a m . a      | s a m . a . m C ., . * (國藥產業投資有限公司)           |
| s am ▼▼ a      | s am ▼▼ a , a m a s a a (\$ : 01696) a a      |
|                | a C m a                                       |
| a a a ( )      | a m a                                         |
| s              | m m s C mm                                    |

## Definitions

|                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>5 C mm</p> <p>5 a a /<br/>5 a Ca a</p> <p>5 a a a a</p> <p>5. 5. a</p> <p>5 a , 5D 5\$</p> <p>5 a</p> <p>5. DA</p> <p>a a a ma</p> <p>a a</p> <p>a a</p> <p>a a</p> <p>a a C ., .* (武漢濟和醫院有限公司), a a C m a</p> <p>C 5 a a D / a m C m a *(《董事有關僱員進行證券交易的書面指引》)</p> <p>a a ma a C m a m *(重慶藥友製藥有限責任公司), a a C m a</p> <p>a C a a a m *(珠海禪誠醫院有限公司), a a C m a</p> <p>%</p> <p>. , a a C am , a , a a , a C a a a a .</p> | <p>5 C mm C m a</p> <p>5 a a C ., .* (宿遷市鐘吾醫院有限責任公司)/5 a Ca a *(宿遷市腫瘤醫院), a a C m a</p> <p>5 a a a a a am a C m a m *(宿遷市新星康復體檢有限公司), a a C m a</p> <p>5. a Am a, a , a 5 a 5. a a D C m a</p> <p>a 5 a</p> <p>a</p> <p>5. a D A m a</p> <p>a a B a ma a C m a m *(江蘇萬邦生化醫藥集團有限責任公司), a a C m a</p> <p>a a m C m a *(溫州老年病醫院有限公司), a a C m a</p> <p>a a a</p> <p>a a C ., .* (武漢濟和醫院有限公司), a a C m a</p> <p>C 5 a a D / a m C m a *(《董事有關僱員進行證券交易的書面指引》)</p> <p>C a a ma a C m a m *(重慶藥友製藥有限責任公司), a a C m a</p> <p>a C a a m *(珠海禪誠醫院有限公司), a a C m a</p> |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|